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ABSTRACT 
 
The overall aim of this research project was to investigate the aerosol performance and 
physico-chemical properties of dry powder formulations produced by co-milling an Active 
Pharmaceutical Ingredient (API- Beclomethasone Dipropionate - BDP) with an additive 
(Magnesium Stearate - MGST), using the jet mill apparatus, for high dose delivery.  
To achieve this, initial experiments were conducted to investigate the effect of changes in the 
concentrations of MGST and BDP, both w/w, on the aerosol performance and physico-
chemical properties of co-milled formulations. Formulations were produced and dispersed 
using a high resistance dry powder inhaler device (RSO1) at a flow rate of 60 L/min using the 
Fast Screen Impactor (FSI). The aerosol performance was tested at capsule fill mass of 10 
mg, 20 mg and 30 mg, respectively.  
To investigate the effect of MGST% w/w concentration, co-milled formulations were 
produced at the set concentration of 1% w/w BDP, varying concentrations of MGST (0%-
7.5% w/w), adding lactose as the final bulking agent. In general, 5% w/w MGST was found 
to be the optimal concentration for aerosol performance in terms of the highest powder 
dispersibility% and emitted dose (ED%) achieved from in-vitro aerosol performance analysis, 
due to the reduction in agglomerate strength and structure as observed from particle size-
shear pressure analysis and Scanning electron microscopy images respectively. 
After this initial investigation, the effect of a range of BDP concentrations (from 1% w/w-
40% w/w) co-milled at a fixed concentration of 5% w/w MGST with lactose as the final 
bulking agent, was investigated to study the effect of BDP concentration on aerosol 
performance. In general, a reduction in aerosol performance in terms of powder dispersibility 
was observed with an increase in BDP% w/w concentration of the co-milled formulations. 
This was due to changes in the physico-chemical properties of the formulation such as the 
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reduction in powder de-agglomeration efficiency, measured from particle size-shear analysis 
and a reduction in the uniformity of content of BDP. High dose delivery (in mg of API) was 
achieved from the co-milled formulations with BDP concentrations < 20% w/w. Furthermore, 
an increase in capsule fill mass also led to the reduction in aerosol performance, likely due to 
an increase in the energy requirement of the inhaler to achieve powder dispersion.  
In the final experiment, the effect of relative humidity (RH-between 50-75% RH) after short 
term storage (0, 1, 5, 15 days, respectively) on the aerosol performance and physico-chemical 
properties of the co-milled formulations (1% BDP/99% lactose and 1% BDP/5% MGST/94% 
lactose) was investigated. Generally, aerosol performance was significantly (p<0.05) higher 
in the co-milled formulation containing 5% w/w MGST, compared to the co-milled without 
MGST, after storage at 75% RH for 15 days. This was likely due to the hydrophobic property 
of MGST which provided a barrier for the adsorption of water molecules on the surface of 
micronised lactose particles, as observed from dynamic vapour sorption analysis, which led 
to the reduction in the extent of agglomerate formation and strength. 
The results from this investigation demonstrated how high dose delivery (in mg) can be 
achieved by co-milling of BDP with the additive material MGST. In addition to improvement 
in aerosol performance, co-milled formulations with MGST showed improved physico-
chemical properties of the powder after storage at elevated humidity (75% RH) compared to 
powders co-milled without MGST.   
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CHAPTER 1: INTRODUCTION 
 
1.1 GENERAL STRUCTURE OF THE HUMAN RESPIRATORY TRACT 
 
The complex structure of the human respiratory tract begin in the upper airways consisting of 
the oral, nasal cavities, pharynx and larynx [1]. Inhaled air from the upper airways enter the 
main windpipe and travel to either the left or right lung by the trachea and the bronchi 
respectively, continuing into the lower respiratory tract consisting of smaller, narrower tubes 
called the bronchioles, which ends at the air sacs referred to as the alveoli [2].  
The tracheobronchial tree is a general term used to describe the general structure of the lower 
respiratory tract, as each parent airway structure splits into smaller airways on average for 
approximately 23 generations [3]. For example, the diameter of the trachea is approximately 
18 mm and branches into smaller structures of the bronchioles, which are approximately 0.5 
mm or less in diameter [4]. The conducting airways of the respiratory tract are the trachea, 
bronchi and bronchioles which are the structures responsible for the delivery of air to the 
lower respiratory tract, and the alveoli is referred to as the respiratory zone, where gaseous 
exchange occur with the systemic blood supply [5]. 
A network of blood vessels is responsible for the continuous supply of blood to and from the 
lung [6]. Oxygen-depleted blood from the body is returned to the right side of the heart and 
pumped to the lung by the pulmonary artery [6]. The artery branches into smaller tubes 
known as capillaries, which are situated in close proximity next or adjacent to the alveoli [6]. 
This forms the site where gas exchange (removal of carbon dioxide and the addition of 
oxygen to the blood) or drug absorption occur between the alveoli and capillary [6]. The 
pulmonary veins carry blood back to the heart, which is subsequently pumped back into the 
systemic circulation [7].              
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1.1.1 ADVANTAGES OF ACTIVE PHARMACEUTICAL INGREDIENTS 
DELIVERY TO THE LUNG 
 
The therapeutic targets of current inhaled active pharmaceutical ingredient (API) therapies 
can be broadly categorised into two groups: 
(1) Localised delivery of API for the treatment of respiratory disease associated with 
inflammation (e.g Asthma, Chronic obstructive pulmonary disease (COPD)), and lung 
infection. 
(2) Systemic drug delivery of proteins or DNA for vaccination and in the management of 
diabetes [8]. 
The following characteristics of the lung facilitate the rapid absorption of inhaled API (within 
minutes to seconds) from the lower respiratory tract : (1) the high surface area of the 
respiratory zone (~ 100 m2) [9], (2) high permeability of the thin epithelial cells in the alveoli 
(~ 0.2 μm) [10], and (3) the small aqueous volume available at the absorption surface (10-20 
mL) that allow for deposition of high API concentration for absorption [9]. Therefore, the 
rate of drug uptake from the lung is the fastest compared to other routes of administration, 
apart from intravenous injection [10]. 
Furthermore, studies suggest the enzymes present in the gastrointestinal tract responsible for 
the first pass metabolism of drugs are not found or have limited functionality in the lung [11]. 
Research by Somers et al., [12] estimates the metabolic activity of the Cytochrome P450 
enzymes in the lung is between 1 to 10% of the activity that has been found in the liver [12], 
which makes the lung an ideal route of administration for API with poor oral bioavailability. 
The advantages of API delivery to the lung are summarised in table 1. 
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Treatment of local respiratory diseases Treatment of systemic diseases 
High API concentration delivered to the 
affected area of the lungs [9]. 
Large surface area (approximately 100 m2) 
of the thin (~ 0.2 μm), highly permeable 
surfaces for API absorption in the alveoli 
[9].  
Rapid therapeutic effect [5]. Suitable in the delivery of API with poor 
oral bioavailability [9]. 
Reduction in the risk for systemic side 
effects [13]. 
Non-invasive (Needle free) alternative for 
the delivery of large API molecules [14].  
 Improved API absorption kinetics from the 
lung compared to oral administration [10]. 
Table 1: Advantages of API delivery to the lung in the treatment of local respiratory and 
systemic disease. 
  
 
 
 
 
 
 
 
15 
 
1.2 MECHANISMS OF DRUG DEPOSITION IN THE LUNG AND 
FORMULATION OPTIONS  
 
1.2.1 PARTICLE SIZE AND DEPOSITION IN THE LUNG 
 
During inhalation, particles which are suspended in the airflow, enter and deposit in the 
respiratory tract of the lung, which is defined as the irreversible physical contact between the 
inhaled particle with the surface of the respiratory tract [15]. Particles which are not 
deposited are generally exhaled from the lung [15].  
The mechanisms for particle deposition in the lung is primarily dependent on the size of the 
particle as demonstrated in (Figure 1): 
                                  
Figure 1: Schematic representation of particle deposition mechanisms in the respiratory tract. 
Figure adapted from [15]. 
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(1) Particles with diameter > 5 μm are primarily deposited in the upper respiratory tract 
(mouth, pharynx, larynx) or at the branches of the bronchial tree by inertial impaction [16]. 
Generally, particles deposited in the upper airways will be cleared by the mucociliary system 
and swallowed, with no significant contribution to clinical effect [15].  
(2) Particles with a diameter in the range of 1 to 5 μm are primarily deposited in the small 
conducting airways and the respiratory zone of the lower respiratory tract by gravitational 
sedimentation [16]. Therefore, respirable particles are regarded as particles with size between 
1 to 5 μm for peak deposition in the alveoli [16].  
(3) Particles less than 1 μm in diameter are primarily deposited in the deep regions of the lung 
by Brownian diffusion [16]. 
(4) Particle deposition by electrostatic precipitation can also occur within the lung, but in 
practice the mechanical mechanisms (impaction, sedimentation, diffusion) are generally 
considered the main mechanisms for inhaled particle deposition [17].   
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1.2.2 INERTIAL IMPACTION 
 
Upon inhalation, particles are suspended in the airflow and travel through the complex 
pathway of the respiratory tract [15]. Changes in the direction of the airflow, which can occur 
due to bifurcation or branching of the airways, result in particles with sufficient momentum 
to separate and exit from the airflow, and subsequently undergo deposition onto the surface 
of the respiratory tract [15]. The probability that a particle will separate from the airflow and 
undergo deposition by inertial impaction is given by the Stoke’s number (Stk):  
       Equation 1                                     Stk = 
Pp d² V
18𝑛𝑅
 
Where R is the radius of the airway, n is the viscosity of air, V is air velocity, Pp is the 
particle density, and d is particle diameter [15]. From the equation, the increase in particle 
size and flow rate increases the probability for particle deposition by inertial impaction.  
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1.2.3 GRAVITATIONAL SEDIMENTATION 
 
The mechanism in which particles deposit in the lower respiratory tract by sedimentation 
from the force of gravity is referred to as gravitational sedimentation, which is proportional to 
the terminal settling velocity (Vts) of the particle, as defined by Stoke’s law (Equation 2), 
where Pp is the density of the particle, Pa is the density of the air, d is the diameter of the 
particle, g is the acceleration due to gravity, n is the air viscosity [15]. 
  Equation 2                                Vts = 
(Pp−Pa) d² g
18𝑛
 
From the equation, an increase in particle sedimentation occurs with the increase in particle 
size. Furthermore, the probability of gravitational sedimentation increases with the residence 
time of particles in the lower airways [15]. This can be achieved by slow, steady breathing 
followed by breath-holding to maximise the residence time of particles in the lower airways 
for particle sedimentation [13] [15].   
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1.2.4 BROWNIAN DIFFUSION 
  
Particle deposition in the lower airways by Brownian diffusion is achieved by the random 
motion resulting from particle collision with other gas molecules [15], and the diffusion rate 
is proportional to the diffusion coefficient (D) of the particle, expressed as: 
     Equation 3                                          D = 
𝐾𝑇
3π𝑛𝑑
 
Where K is the Boltzmann’s constant, T absolute temperature, n is the gas viscosity and d is 
the particle diameter [15]. Deposition of particles by Brownian motion increases with the 
decrease in particle size [15].  
 
1.2.5 ELECTROSTATIC PRECIPITATION 
 
The generation of aerosols from inhaled drug delivery systems can lead to significant 
electrostatic charges being imparted on the droplets or fine particles [18, 19]. During 
inhalation, the charged particles may induce an equal and opposite charge on the surface of 
the airways which lead to particle deposition by electrostatic precipitation [19]. The extent of 
the electrostatic charge on inhaled particles can be used to control the regional deposition 
pattern within the respiratory tract, as demonstrated by previous research [18, 20, 21]. 
 
 
 
 
20 
 
1.2.1 CURRENT INHALATION DELIVERY SYSTEMS 
 
Currently, inhaled API can be formulated as dry powder inhalers (DPIs), pressurised metered 
dose inhalers (pMDIs), or nebulisers. 
1.2.1.1 DRY POWDER INHALERS 
 
Dry powder inhalers are breath actuated devices making it easier for the patient to use in 
comparison with pMDIs; furthermore, are propellant free, improving the physico-chemical 
stability of the API [22] [23]. Important physicochemical properties include: whether the 
particle is crystalline or amorphous, particle size, and solubility. Disadvantages include the 
need to generate high inspiratory flow in some DPIs, which generally cannot be achieved in 
certain patient groups such as young children (less than 5 years old), the elderly, or in patients 
with reduced lung function [22].  Variables which need to be considered in the design and 
development of a successful DPI delivery system include the physico-chemical properties of 
the ingredients in the dry powder formulation, the characteristics of the inhaler, and the 
inspiratory flow rate of the patient [23] [24].  
1.2.1.2 DELIVERY OF LOW DOSE FORMULATIONS – AGGLOMERATE 
AND CARRIER APPROACH 
 
Currently, two formulation approaches are generally used for the production of dry powder 
formulations: 1) a carrier based approach for the production of an interactive mixture of 
micronised API (< 5 μm) attached onto the surface of the larger carrier particle (typically 
lactose ~ 60-90 μm) [25, 26]; and 2) a particulate system comprised of similar sized particles 
in the production of an agglomerated dry powder formulation [23]. Irrespective of the 
formulation approach, micronised particles are highly cohesive/adhesive materials due to the 
presence of inter/intra particulate interactions, such as Van der Waals, electrostatic and 
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capillary interactions [15]. Inter-particulate interactions refer to the interaction between 
particles in adhesive materials, while intra-particulate interactions refer to the interaction 
between particles in cohesive materials [15]. The extent of the cohesive/adhesive interactions 
can influence the amount of the API delivered to the deep regions of the lung, as the 
particulate interactions can prevent the liberation of API from either the carrier or from 
agglomerates in the dry powder formulation [15].  
1.2.1.3 CARRIER FORMULATION APPROACH 
 
Carrier based formulations have been developed to overcome the issues associated with soft 
aggregate formulations, and is produced from the physical mixture of the micronised API (<5 
μm) with the larger (~ 60-90 μm) carrier, which result in the attachment of the API onto the 
surface of the carrier particles [15, 26]. This system leads to the physical separation and the 
reduction in the interaction between micronised particles, therefore minimises the formation 
of cohesive agglomerates that are detrimental to aerosol performance [27-29]. Carrier lactose 
particles are typically the most commonly used excipient in commercial dry powder 
formulations, as it’s safety and stability profile has been extensively investigated, is readily 
available, and relatively inexpensive to manufacture [30].  
The advantages of carrier based formulations include: 
(1) An improvement in the flowability of micronised API which are attached onto the 
surface of the coarse carrier [25]. Powder flowability is a general term to describe the 
extent of powder flow which can be affected by the physico-chemical properties of 
the particles [25].  
(2) Enhanced dose metering accuracy for low dose delivery (typically in the range 100-
600 μg) and uniformity of content of dry powder formulations[23] [31]. 
22 
 
The main challenge associated with carrier based formulations is achieving a balance in the 
extent of the surface energy of interactions between the API and the carrier, which must be 
strong enough such that the API does not become dislodged upon product handling and 
transport, while being weak enough such that the API is liberated from the carrier upon 
inhalation [15, 32]. The presence of active sites on carrier particles can lead to strong inter-
particle interactions between the API and carrier [33]. Active sites on the surface of carrier 
particles include amorphous regions, surface cavities or regions with high surface energy [15, 
34]. The inter-particulate interactions between the carrier and the API are often too strong for 
efficient drug liberation from the carrier particles upon inhalation, and result in a low FPD 
(Fine particle dose – the amount of API less than 5 μm in size recovered from the fine 
particle stage(s)) as analysed from in-vitro aerosol performance [34-38]. The aerosol 
performance of a DPI in this thesis refer to the FPD of the formulation. Therefore, there is a 
general need to improve the FPD in modern DPI. As reviewed by Yang et al., and Steckel et 
al., [39, 40], the lung deposition profile of current carrier based DPIs formulations are 
relatively low, within the range of 20-40%. For example, the reported FPF% of first 
generation DPIs such as the Spinhaler® were approximately 10% [41], generation two 
devices like the Handihaler, achieved more than 20% FPF% [42], and newer devices like 
Genuair® can now achieve an FPF% of approximately 30-40% [43]. 
Strategies to improve the aerosol performance of binary formulations have in the past focused 
on the physico-chemical aspects of the carrier such as: (1) carrier particle size [44-46], (2) 
surface area [47, 48], intrinsic lactose fines [49-51], and pre-blended carrier with micronised 
excipient particles that bind to and saturate the high energy sites on the carrier, therefore 
improving the dispersibility of API [32, 37, 51-54]. Dispersibility is a measure in the amount 
of fine particles (< 5 μm) that reach the deep regions of the lung [32].  
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While such strategies can be used to improve the aerosol performance in low dose drug 
delivery, a carrier based formulation would not be suited for the delivery of higher doses (in 
mg), due to the active site saturation of carrier particles which can lead to fine particle 
segregation, and subsequently the formation of agglomerates that can negatively affect the 
dispersibility and flowability of the formulation [31].  
1.2.1.4 CARRIER FREE AGGLOMERATE FORMULATION APPROACH 
 
Carrier free formulations for the delivery of low doses can be achieved by the micronisation 
of the API, with or without excipients as bulking agents, to produce a powder bed of soft 
aggregates by spheronisation [55]. Such aggregates usually remain intact for dose loading 
and handling purposes, but are easily de-agglomerated into primary particles upon patient 
inhalation [55, 56]. Desiccant can be stored in the operating unit of the inhaler to protect the 
aggregates from moisture, which may harden the aggregates and affect the aerosol 
performance of the formulation [55].  
Since it is generally accepted that particles with a mass median aerodynamic diameter 
(MMAD) in the range of 1-5 μm are deposited into the deeper regions of the lung [13], the 
agglomerates in the formulation must be de-agglomerated from the forces generated by the 
patient’s inspiratory flow rate [57]. The major limitation of a soft aggregate formulation is 
that only a small fraction of the API within the respirable size range is inhaled by the patient, 
as measured by the low fine particle fraction of the formulation (FPF%, the amount of fine 
particles <5 μm that are delivered to the lower regions of the lung) from in vitro aerosol 
performance analysis due to the highly adhesive/cohesive nature of micronised particles, 
which experience high inter/intra particulate interactions including Van der Waal’s, capillary, 
and electrostatic forces that promote spontaneous agglomerate formulation [15, 27] . This 
leads to either the retention of the agglomerates within the interior of the DPI device or the 
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release of stable agglomerates larger than 5 μm which do not reach the deeper regions of the 
lung [31].  
For example, the aerosol performance of a loose aggregate formulation delivered from 
passive DPI achieved for the Spinhaler and Turbohaler  devices has been found to be 10.13% 
and 24.64%, respectively [40, 42]. Furthermore, loose aggregates can exhibit high variability 
in terms of powder flowability, dose emission and uniformity of content which are 
detrimental to the aerosol performance of the formulation [31, 32, 58].  
1.2.1.5 COHESIVE/ADHESIVE PARTICLE INTERACTIONS IN DRY 
POWDER 
 
Particle interactions refers to the long range, physical forces of attraction between particles, 
characterised by weak bonding energies of less than 40 kJ/mol [15]. The interactions between 
particles can have an effect on various properties of the dry powder formulation including 
flowability, mixing, and particle de-agglomeration efficiency [15]. Particle interactions can 
be generally classified as either: 
(1)  Cohesive interactions between particles of similar physico-chemical properties such 
as structure and size [59] . Therefore, the extent of particle interaction between 
adjacent particles is known as the cohesive force. 
(2)  Adhesive interactions between particles of different physico-chemical properties, for 
example the adhesive force between a particle and a larger surface [59].  
The general mechanisms of particulate interactions in DPI formulations include Van der 
Waals, electrostatic, and capillary force.  
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1.2.1.6 VAN DER WAALS INTERACTIONS 
 
Van der Waals forces is the dominant cohesive and adhesive force of interaction between 
adjacent particles and between particles with the interacting walls of the apparatus (such as 
inner walls of the DPI) during powder fluidisation [27]. The interactions occur between 
particles with momentary changes in their electron densities and configurations, which result 
in the attraction between dipolar particles [27]. The following equation (Equation 4) describe 
the relationship of the Van der Waals force (Fvdw) between two identical spheres [60]:  
Equation 4:                                                Fvdw  =
ARs
  12𝑎2  
 
Rs is the radius of the spheres, a is the separation distance between particles, A the Hamaker 
constant (A = 10-20 J). 
A reduction in separation distance between particles occurs with the reduction in the particle 
size. Therefore, respirable particles (1-5 μm) generally experience significant high levels of 
Van der Waals forces of interaction [27]. 
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1.2.1.7 ELECTROSTATIC INTERACTIONS 
 
Generally, particles in dry powder formulations come into contact with other particles and 
with surfaces during various manufacturing steps such as powder mixing, micronisation, and 
dose loading [21]. Furthermore, contact between the particles and the surface of the DPI 
during dose actuation can occur. During these processes, the exchange of electrons between 
the contacting materials is possible due to differences in surface potentials, resulting in the 
development of electrostatic charge by triboelectrification [21] [61]. In addition to contact 
charge, triboelectrification can also occur by sliding and friction forces between particles 
[15]. Electrostatic charge can lead to an increase in the force of cohesion between two 
opposite charged particles, which can affect the aerosol performance of the formulation [27]. 
1.2.1.8 CAPILLARY INTERACTIONS 
 
In a high humidity environment (>65% RH), adsorption and condensation of water molecules 
in the spaces between particles can occur, resulting in capillary interactions which can lead to 
the further increase in particle cohesion as represented in the following equation [27]: 
  Equation 5:                                      Fc= 2 πRY 
Where Fc is the maximum capillary force, R is the radius of the sphere, Y surface tension of 
the liquid. Capillary interactions can affect the aerosol performance of dry powder 
formulations as previously reported [62, 63]. 
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1.3 OTHER INHALATION DELIVERY SYSTEMS 
 
1.3.1 PRESSURISED METERED DOSE INHALERS 
 
In general terms, pMDIs can be formulated either as a homogenous suspension or solubilised 
API in a liquid mixture containing the propellant and excipients such as surfactants and/or co-
solvents [64]. The formulation is enclosed within a canister connected to a metering valve, 
which upon actuation, releases a metered volume of the API and propellant that is inhaled by 
the patient [64]. The metering valve typically has a volume between 25-63 μL, which 
generally limits the amount of drug released per dose to between 50-250 μg, making pMDI’s 
unsuitable in high dose delivery [65]. 
Advantages of pMDIs include it’s portable design which allow for convenient, multi-dose 
drug delivery to the lung [66] .  A major disadvantage is the need for coordination between 
device actuation and breathing, which can lead to significant variability in delivered dose 
depending on the patient’s coordination technique [67]. Additionally, the solubility and poor 
physico-chemical stability of the API in different propellant or excipients are significant 
limitations to the range of APIs that can be formulated [68, 69].   
1.3.2 NEBULISERS 
 
Nebulisers are devices which, in general, use either compressed gas (Jet nebulisers) or 
ultrasound (Ultrasonic nebulisers) to generate inhaled aerosols from liquid in the form of a 
solution or suspension [66]. The main advantage of a nebuliser compared to pMDI and DPI is 
no special patient inhalation technique is required, making it a preferred drug delivery 
platform in the elderly or young children [66, 70] . Disadvantages include the need for 
compressed gas or a compressor in the operation of the device, reducing the device’s 
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portability, lower delivery efficiency (approximately less than 10% of the drug reaches the 
lung [71, 72] and longer treatment time compared to pMDIs and DPIs [66]. 
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1.4 FOCUS OF THE THESIS 
 
As summarised in this chapter, inhaled API therapy offer numerous advantages in the 
treatment of both local lung and systemic diseases. However, there are various challenges 
associated with the delivery of micronised API from DPI, which is summarised in chapter 2, 
with a review of the current limitations associated with both low and high dose delivery of 
DPI formulation, and the application of the “co-milling” technique in the production of dry 
powder formulations to overcome such limitations. The technique of co-milling and the effect 
on powder dispersibility, physico-chemical properties, and powder stability forms the 
primary focus of this thesis.  
In chapter 3, the investigation of the different concentrations of MGST% w/w and BDP% 
w/w, respectively, in co-milled formulations on the aerosol performance and physico-
chemical properties of dry powder formulations for high dose delivery is presented.  
As micronisation introduce physico-chemical instability and changes to micronised particles 
in regards to its crystalline structure, in chapter 4 the investigation of whether co-milling with 
MGST could improve the physico-chemical properties and aerosol performance of DPI 
formulations after storage at elevated humidity for 0, 1, 15 days respectively, compared to co-
milling without MGST is presented.  
A general conclusion of the thesis is discussed in chapter 5 along with future work. 
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CHAPTER 2: REVIEW 
A REVIEW OF CO-MILLING TECHNIQUES FOR THE PRODUCTION OF HIGH DOSE 
DRY POWDER INHALER FORMULATION 
                                                      2.1 INTRODUCTION 
Drug delivery to the lungs offers several advantages compared to other routes of 
administration, including: a lower dose to achieve an equivalent therapeutic effect (i.e. 100-
200 µg dose by inhalation is therapeutically equivalent to an approximate 2-4 mg oral dose of 
salbutamol sulphate (SS)) [1, 2]; rapid drug absorption from the large surface area of the 
lung, which is highly perfused with systemic blood supply [1]; and, the ability to bypass first-
pass metabolism [3, 4]. Therefore, these advantages offer enormous potential for the delivery 
of active pharmaceutical ingredients (API) in the management and treatment of lung 
conditions, such as asthma, chronic obstructive pulmonary disease, and respiratory infections 
[2,5]. 
Lung delivery can be achieved by using different formulation approaches in which the API is 
delivered in the form of a dry powder or droplets, with or without excipients [5]. 
Traditionally, dry powder formulations are categorised as either micronised particles of soft 
aggregates, or more commonly, as a binary mixture consisting of micronised API and a larger 
diameter (for example 60-90 µm) [5] carrier, generally lactose, for the delivery of low doses 
(typically in the µg range; ~ 6-600 µg) [5]. 
The past 10 years has seen an increased interest in the delivery of dry powder formulations 
for new therapeutic indications, including antibiotics (lung infection) [6], hypoglycaemic 
(diabetes) [7], and anti-viral medicines (viral infection) [8]. Therefore, there has been a focus 
on higher dose formulations (typically in 10s of mg [6]). Examples of these high dose dry 
powder formulations include: 
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(1) TOBI® Podhaler® DPI (approved in 2013) containing tobramycin (28 mg per capsule, 
four capsules inhaled twice daily) dry powder formulation using the PulmoSphere® 
technology, approved for the treatment of chronic pseudomonas infections associated with 
cystic fibrosis [6, 9, 10]. 
(2) Dreamboat™ DPI (approved in 2014) for the delivery of either 4, 8, 12 international units 
(I.U - with one 4 I.U equivalent to 0.35 mg of insulin, 8 I.U equivalent to 0.7 mg insulin, and 
12 I.U. equivalent to 1 mg of insulin, respectively) of rapid acting recombinant insulin in the 
management of type 1 and 2 diabetes from pre-metered plastic cartridge formulated with 
Technosphere® technology [11, 12]. 
(3) Lanavir® DPI (approved in 2010) for the delivery of Laninamivir (40 mg) in the 
treatment and prophylaxis of influenza A and B viral infections [13]. 
Furthermore, inhaled antibiotics containing high doses of ciprofloxacin, levofloxacin, and 
amikacin are also in various stages of the research and development pipeline [6, 13, 14]. 
Co-milling of the API with additives and excipients is a means of producing high efficiency, 
high dose powders for DPIs [15]. Co-milling involves, co-processing two or more 
components through a mill to achieve a homogenous powder blend, either by an ordered mix 
or coating [15]. The focus of this review is to examine the application of co-milling as a 
potential method for production of DPI, specifically focusing on the method as a means to 
obtain high dose dry powder drug delivery. The additives and excipients used in co-milling 
are discussed and the current challenges and limitations associated with the production of dry 
powder formulations for the delivery of low and high doses are examined. Currently, no co-
milled formulations exist as DPI products. 
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2.2 ADDITIVES AND APIs USED IN CO-MILLED DPI 
FORMULATIONS  
 
Micronised particles (<5 μm) are highly cohesive/adhesive particles due to the changes to 
surface area, surface energy and particle size after micronisation [5]. The increase in surface 
energy with the reduction in particle size leads to increased tendency of micronised particles 
to form highly cohesive agglomerates with reduced dispersibility and flowability 
properties [15]. 
Furthermore, the introduction of amorphous regions during the micronisation process of 
crystalline materials can lead to physico-chemical instability upon exposure to a high 
humidity environment [5, 16]. Specifically, the formation of solid bridges associated with the 
re-crystallisation of amorphous regions after storage at high humidity levels can lead to the 
formation of cohesive agglomerates, which can cause a subsequent reduction in the overall 
aerosol performance of the formulation [16-19]. 
This limitation can be overcome by co-milling API with additive material to produce 
composite particles with enhanced aerosol properties. This is achieved from the selection of 
additive materials with: 
(1)   Anti-adherent properties that reduce the cohesive/adhesive interactions 
experienced by the API, either between adjacent particles or to the surfaces which 
the particles are exposed to [15]. This leads to a reduction in agglomerate strength 
and subsequent improvement in the dispersibility and aerosol performance of the 
formulation [15]. 
(2)   Anti-friction properties to improve powder flowability in addition to accurate 
dose metering and dose emission of the API [15, 20]. 
(3)   Hydrophobic properties to minimise the re-crystallisation of amorphous regions in 
micronised particles upon storage at elevated humidity environment [15]. 
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Generally, a minimal amount of the additive material sufficient to achieve a single layer 
coating of each powder component to improve the aerosol performance of the formulation is 
recommended, due to economical and toxicity considerations associated with the use of the 
additive material [15]. Furthermore, additives are chosen to possess the following properties: 
non-irritant, easily metabolised/cleared, and non-toxic to the lung [21]. 
In this review, co-milling is a general term to describe the co-processing of either the API or 
the excipient particle with the additive material for the production of composite particles with 
enhanced dispersibility and flowability properties. This can be achieved in various 
apparatuses, which in the case of the jet mill and ball mill are generally associated with 
particle size reduction, while in the case of the mechanofusion apparatus is not associated 
with particle size reduction. A brief summary of the co-mill technique is given in Figure 1 
below, and the application of co-milling in the production of high dose dry powder 
formulations will be explored in the following sections. 
  
  
  
 
Figure 1:  Co-milling technique schematic for the co-processing of the API or excipient 
particle with the additive material. Co-mill by mechanofusion result in the production of 
composite particles of API/excipient particles with surface coverage by additive material 
without change in particle size. Co-mill by jet or ball mill result in the production of 
composite particles with reduction in particle size of the API/excipient and additive material. 
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2.3 CO-MILLING TECHNIQUES 
 
2.3.1   JET MILL TECHNIQUES 
 
The jet mill is an established and validated apparatus for the micronisation of particles to a 
size suitable for inhalation and, in general, is capable of producing particles between 1-
15 μm, within a narrow size range [22]. It is a standard apparatus widely used by the 
pharmaceutical industry in the production of micronised API formulations [23]. The 
advantages and disadvantages of the jet mill apparatus are listed in Table 1 below. 
Advantages Disadvantages 
Micronisation to a size suitable for 
inhalation (1-5 μm) [26]. 
Generation of amorphous regions on the 
micronised particles [24]. 
Well validated and established method [26]. Formation of solid bridges between 
particles from the re-crystallisation of 
amorphous regions on milled particle 
surface [23]. 
Self-classification system for separation of 
particles based on size [27]. 
The production of small, electrostatically 
charged particles, with flat irregular 
surfaces of high surface areas that promote 
the adhesion and cohesion between surfaces 
and particles respectively, affecting powder 
flow and dispersion properties [25, 26]. 
No moving parts as micronisation is 
achieved by particle collision, resulting in 
Lack of control in the physical properties of 
the final micronised particles such as the 
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little to no product contamination [26]. shape and morphology [23]. 
Easy to use, easy to clean and relatively 
inexpensive micronisation apparatus. 
Not generally suitable for fragile, porous or 
hollow particles [23, 26]. 
Table 1: Advantages and disadvantages of the jet mill apparatus. 
 
A standard jet mill design consists of a product inlet stage where materials to be micronised 
are fed into the grinding chamber. The rate at which materials are fed into the jet mill is 
referred to as the feed rate (g/min) [26]. Within the inlet stage, the injection pressure, 
generated by the flow of compressed gas through the venturi system, force the particles to 
accelerate at high velocities into the grinding chamber of the jet mill [27, 28]. The grinding 
chamber is a flat disk shaped chamber with “grinding nozzles” that generate a region of high 
pressure by compressed gas, referred to as the grind pressure [29]. Subsequently, particles 
undergo multiple particle-particle and particle-wall impactions, which induce particle fracture 
and subsequent size reduction [30]. 
Furthermore, the rotating vortex created in the grinding chamber allows for simultaneous 
particle size classification, as larger particles are pushed by centrifugal force onto the outer 
perimeter of the grinding chamber and remain in rotation for further micronisation, while fine 
particles leave the grinding chamber through the central outlet zone with the drag force 
generated by the compressed gas [29]. Micronised particles are collected from the collection 
chamber, located below the central outlet zone of the grinding chamber, which collects the 
majority of the final micronised product [22]. This ensures fine particles are separated from 
the coarse particles and allow for self-classification based on particle size. A schematic of the 
grinding chamber is presented in Figure 2 below. 
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 Figure 2: Schematic representation of the grinding chamber of the jet mill apparatus. 
 
The main variables of the jet mill which can affect its ability to micronise materials include: 
1) The grinding chamber diameter, along with the number and angle of the grinding    
nozzles [31]. As the diameter of the grinding chamber increases, so does the feed rate  
(g/min) and volumetric flow rate of the mill, giving rise to the following relationship  
between the solid feed rate (Q) which is proportional to the diameter of the mill chamber  (D) 
[31] (Equation 2), 
Equation 2:                               Q ∝ D2.8 ± 0.2  [31] 
In this equation the grinding capacity of the mill is increased with an increase in the 
diameter of the grinding chamber. 
The number of nozzles within the grinding chamber is also important. An increase in 
the number of nozzles up to a total of 12 was reported to have produced the best 
results, likely due to greater consistency in the flow of particles within the chamber 
[31, 32]. Furthermore, the angle of the nozzles will determine the distance between 
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the grinding region and the central outlet, and therefore the intensity of particle 
collisions during micronisation [31]. The optimal angle according to previous studies 
is between 52 and 60° [31, 32]. 
 
2) The feed rate, grinding pressure, and injection pressure [31]. Feed rate plays an important 
role in the micronisation process. A slower feed rate provides greater opportunity for higher 
energy to be imparted from the injection and grind pressures onto fewer particles over time, 
resulting in greater particle–particle interactions and subsequently particle fracture and 
micronisation [30, 33]. As the feed rate increases, the energy from the injection/grinding 
pressures is distributed over a larger number of particles reducing the kinetic energies 
imparted [30,33]. This may result in less high-speed particle-particle interactions and 
therefore lower micronisation efficiency [30, 33].  
Generally, higher grinding pressure results in further particle size reduction, while the 
injection pressure is important to prevent blowback of particles from the venturi system [30]. 
For example, the optimal parameters for milling lactose was reported to be at high grinding 
and injection pressures of 110 psi and 65 psi, respectively, in the production of lactose 
particles with the smallest size distributions (D50 ~ 2.99 μm and D90 ~ 7.54 μm,  
respectively) [34]. Lower injection pressures, below 20 to 33 psi, can cause significant “blow 
back” of the material, therefore reducing the yield of the final product [34].  
Similar results were reported in a study of the optimal parameters for the micronisation of a 
common API, SS [22]. Grinding pressure had the most significant influence on particle size 
reduction; pressures less than 6 bar did not provide sufficient micronisation energy for size 
reduction, while no further reduction in particle size was observed at grinding pressures 
greater than 6 bar, as the maximum jet speed was achieved [22]. The injection pressure was 
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important in preventing blowback or discharge of the product and the increase in feed rate did 
not give raise to a significant increase in particle size [22]. The optimal parameters for best 
particle size distribution for SS was an injection pressure of 7.5 bar, grind pressure 6 bar and 
feed rate 2.5-5 g/min, respectively when using the jet mill apparatus [22]. 
In a patent filed by Morton et al., [15] the size of the composite particles produced after co-
milling the additive and API was primarily dependent on the grinding pressure; grinding 
pressure between 1-2 bar resulted in the blend of the host and additive particles, with the 
surface coverage of the host particle by the additive material without significant reduction in 
particle size [15]. At higher grinding pressures between 5-12 bar, simultaneous micronisation 
and surface coating of the host particle by the additive material was achieved, such that 
composite particles with a D50 between 3 and 0.5 µm was produced [15]. Therefore, the 
operating parameters of the jet mill can be adjusted to produce composite particles with 
various degrees of coating and size reduction which are tailored for optimised delivery of 
API [15]. 
The production of high dose, co-milled API and additive in carrier free formulations was 
demonstrated by Morton et al., [35]. The procedure used included: an initial mix (in a pestle 
with a spatula) of the pre-micronised API (Clomipramine hydrochloride) (in a jet mill at 7 bar 
injection pressure, 5 bar grinding pressure at 10 g/min feed rate) 95% w/w with 5% w/w of 
magnesium stearate (MGST), which was subsequently passed through the jet milled at 
injection pressure of 7 bar, grinding pressure of 1 bar and powder feed rate of 10 g/min to 
achieve composite particles with a D50 of 1.38 μm [35]. Similarly, micronised API was 
prepared with the same settings in the jet mill (7 bar injection pressure, 5 bar grinding 
pressure at 10 g/min feed rate) to allow for the comparison in aerosol performance. In-
vitro aerosol performance was tested using an Aspirair DPI, at 2 mg dose fired into a Next 
generation impactor (NGI) at flow rate of 60 L/min. The co-milled formulation with 5% w/w 
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MGST significantly reduced the % retention of the API from the device (from 26% to 6%, 
respectively) and improved the emitted dose (ED), Fine particle dose (FPD) and Fine Particle 
Fraction (FPF %), respectively compared to micronised API only (ED 1.67 mg, FPD 1.35 
mg, FPF 81% (of metered dose (MD)) compared to ED 1.19 mg, FPD 1.05 mg, FPF 64% 
(MD), respectively) [35]. The advantage of the two stage processing of API included the 
initial micronisation of the API to a size suitable for inhalation at high grinding pressure, 
followed by a second co-mill stage where the API is mixed with the additive at the lower 
grinding pressure for the production of composite particles with improved aerosol 
performance compared to single stage micronisation of API only. 
High dose delivery of apomorphine hydrochloride was demonstrated by another research 
group [36]. 9 g of micronised apomorphine and 1 g of micronised Leucine (LEU) was mixed 
in a mechanofusion system at 20% (1000 rpm) for 5 minutes. The blend was passed through a 
AS50 Spiral air jet mill at 7 bar injection pressure and 5 bar grinding pressure, at 5 mg/min 
feed rate. Aerosol performance was tested using an Aspirair DPI and an average fine particle 
dose of 1.59 mg was achieved with a FPF% (ED) of 96% and low throat 2% and device 
retention 10% [36]. 
A study by Stank et al., [37] investigated the co-milling of a model API (SS) with various 
additives, and evaluated the aerosol performance and the physico-chemical properties of each 
formulation. The two additives chosen were MGST, and Glycerolmonostearate (GMS) [37]. 
Formulations with various concentrations of MGST (1%, 2%, 5% and 10% w/w) and GMS 
(2%, 5% and 10% w/w) were mixed with SS before micronisation in a jet mill at 7 bar 
injection pressure and 6 bar grinding pressure [37]. In this experiment, the co-milling 
procedure produced composite particles with reduced, homogenous surface energies, 
compared to the initial raw materials as measured by dispersive surface energy 
distribution [37]. The reduction in the surface energies of the composite particles led to the 
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reduction in agglomerate strength, which subsequently improved powder flowability 
(assessed by powder rheology) and de-agglomeration, with the highest FPF% achieved at 
10% w/w MGST of 41.5 ± 2.4% compared to conventional blended formulation (FPF% ~ 
20%) [38]. 
In summary, compared to milling alone, the advantages of the co-milling technique for the 
production of high dose formulations include: 
(1)  The coating of the API by the additive material during the co-mill process provides a 
physical barrier that reduces the forces of interaction between micronised particles, and a 
reduction in the force of adhesion between particles and the internal surfaces of the DPI 
device, therefore improving powder flowability and dispersibility upon inhalation [15]. 
(2) The presence of the additive material improves the efficiency of the micronisation 
process with further reduction in the composite particle size compared to formulation 
without additive material. This can lead to further improvement in the FPD and FPF% of 
the formulation [15]. 
(3)  Multiple milling process can be used to produce highly dispersible composite particles.  
For example, a two process step of jet milling can be used for the initial reduction of API 
particle size, followed by a second co-mill step of the micronised API with additive to 
produce the final homogenous formulation. This approach was demonstrated to produce 
finer particles with reduced throat deposition when compared to a single process step of 
co-milled API with additive at high grinding pressure [15]. 
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2.3.2 BALL MILL TECHNIQUES 
 
The ball mill apparatus can be used to micronise materials to a size suitable for inhalation (<5 
µm), but it is generally a very slow process that includes multiple processing steps making it 
poorly scalable for industrial use [23]. The advantages and disadvantages of the ball mill 
apparatus are presented in Table 2. 
 
Advantages Disadvantages 
Particle size reduction to a size range 
suitable for inhalation [41]. 
Potential for powder compaction on the 
walls of the milling vessel [40]. 
Simultaneous micronisation and surface 
coating of API with additive material [41]. 
The need for multiple processing steps and 
use of solvents in wet ball milling [40]. 
Table 2: Advantages and disadvantages of the ball mill apparatus 
 
A typical ball mill apparatus consists of a vessel filled with milling apparatus (balls or rods) 
which can be constructed from materials such as ceramic, agate, and silicon nitride [39]. 
Materials to be micronised (Feed material) are placed inside the vessel which is subsequently 
rotated at a specific speed or frequency leading to the collision between the feed material 
with the milling apparatus or the surface of the vessel [39]. Therefore, the micronisation 
process is dependent upon two main forces imparted on the feed materials: 1) The forces of 
impaction between the feed material and the milling apparatus; and 2) The forces of attrition 
experienced by the feed material from the movement of the milling apparatus relative to each 
other [39]. A schematic representation of the ball mill is presented below in Figure 3. 
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Figure 3: Schematic representation of the ball mill apparatus. Figure adapted from [41]. 
 
The extent of the particle size reduction is generally dependent on the following parameters: 
(1)  The rotating speed (velocity) of the vessel. At low velocity, minimal particle size 
reduction is achieved due to the generation of low intensity micronisation forces; as there 
is little movement in both the milling apparatus and the feed material within the rotating 
vessel [41]. At high velocity the milling apparatus and the feed material are forced 
towards the wall of the vessel by centrifugal force which also result in minimal particle 
size reduction [41]. About two thirds of the critical velocity, the milling apparatus move 
in a cascading pattern as it is lifted by the rising side of the vessel, and roll or fall back to 
the base of the vessel [41]. This is the most efficient vessel speed for particle size 
reduction from the impaction and attrition forces [41, 42]. 
(2)  Generally, greater particle size reduction is achieved at longer milling times [43]. 
(3)  The intensity of the milling process is dependent on the quantity of both the starting 
material (feed material) and of the milling apparatus [39, 44]. The amount of API and/or 
excipient materials is an important factor in the milling efficiency, as an excessive 
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quantity can lead to a reduction in micronisation efficiency and too little result in abrasive 
wear and tear of the milling apparatus [41]. Generally, the vessel is filled with the milling 
apparatus and material to be micronised up to 50 to 25% of the total volume of the vessel, 
respectively [39]. Furthermore, the size, density, and material hardness of the 
micronisation apparatus affect the rate and extent of particle micronisation, a decrease in 
the size and/or an increase in both the density and hardness of the micronisation apparatus 
generally result in an increase in the rate and extent of micronisation [39, 45, 46]. 
The production of high dose, carrier free, dry powder formulations consisting of composite 
particles in a size suitable for inhalation was achieved by co-milling SS with additive material 
(MGST) as demonstrated by Staniforth et al., [47]. 5 g of micronised SS (D50 <5 µm) and 0.5 
g of MGST were processed in a 50 cm3 stainless steel vessel together with 20 
cm3 dichloromethane and 124 g of 3 mm stainless steel balls at 550 rpm over 5 hours [47]. 
Composite particles between 0.1 to 0.5 µm was observed under Scanning Electron 
Microscopy (SEM). However, as the powder was highly agglomerate, further processing in a 
ball mill with a mixture of ethanol, polyvinylpyrrolidone, HFA227 liquid propellant and 
subsequently spray dried was used to produce the final formulation. Final composite particles 
suitable for inhalation of aerodynamic size between 0.1 to 4 µm was achieved. Aerosol 
performance was not reported. 
Another group demonstrated improvement in particle size reduction after co-milling a model 
API with additives [45]. In this study, a model API (chitosan, median diameter 275 µm) was 
pre-ball milled to ~ 5 µm diameter before subsequent ball milled with different fatty acid 
additives of different acyl chain length (i.e. Lauric, Myristic, Palmitic and Stearic acid). It 
was reported that an increase in the hydrophobicity of the fatty acid led to greater reduction in 
size reduction of API, and of that stearic acid, with the longest acyl chain, was most effective 
in production of fine particle composite suitable for inhalation (1.8 µm median diameter). 
51 
 
The delivery of high doses of the API by co-milling with additive material using the ball mill 
apparatus has also been investigated. Research by Lakio et al., [21] investigated the co-
milling of API (L-arginine) with either L-LEU or MGST. Formulations prepared were 80% 
w/w of API with 20% w/w LEU and 98% w/w API with 2% w/w MGST. Ball milling at 500 
rpm was conducted using a bowl size 250 ml with 100 x 400 g, 10 mm diameter stainless 
steel balls. Using the Monodose dry powder inhaler with a capsule fill mass of 20 mg, high 
dose delivery with adequate dose emission was achieved at 90 L/min. Specifically, a fine 
particle dose of 1.51 mg and 3.94 mg, and emitted dose of 87.14% and 90.86% were reported 
for co-milled formulations with MGST and LEU, respectively. 
Alternatively, the ball mill apparatus can also be used to reduce powder caking and 
agglomeration after the production of high dose formulations. As demonstrated by Staniforth 
et al., [47], caking in MGST powder was broken by ball milling the powder for 1 minute to 
produce homogenised MGST with particle size less than 2 µm. Two blends of SS and 
homogenised MGST were prepared (19:1 or 3:1 ratios) and were subsequently processed in a 
Hosokawa Mechano-Fusion AMS-mini device to produce final co-milled formulation. Both 
blends achieved a FPF% of 66% compared to un-processed SS with 28%. 
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2.3.3 MECHANOFUSION 
 
Mechanofusion is a dry coating process where the additive material is fused onto the surface 
of a host particle, commonly the API or excipient, in the production of composite particles 
[48]. Typically, a nanometer coating of the additive material on the host particle is 
achieved [48]. Therefore, the aim is to choose additive materials which have anti-adherent 
and/or anti-friction properties to impart beneficial properties on the host particles in terms of 
an improvement in aerosol performance such as flowability or dispersibility. The advantages 
and disadvantages of the mechanofusion system is given in Table 3. 
Advantages Disadvantages 
Application of compression and shear forces 
for the fusion of the additive material onto 
the surface of the API in the production of 
composite particles with improved 
flowability and dispersibility [15]. 
Deformation of the particle shape to a 
rounder shape with little to no size reduction 
of API [48]. 
Surface coating of the API with the additive 
material [48]. 
The need for multiple processing steps as in 
the micronisation of the API for particle size 
reduction before processing by 
mechanofusion [50]. 
Little to no impaction between the particles 
and the milling media surfaces which 
minimises product contamination [15]. 
  
Table 3: Advantages and disadvantages of mechanofusion. 
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A typical mechanofusion system consist of a large rotating outer vessel which can rotate at 
speeds up to 5000 rpm [49], a stationary inner piece and scraper. The materials are placed 
into the vessel, which then rotates and force the particles towards the walls of the vessel by 
centrifugal force [50]. The particles experience high shear and compression forces as they 
pass the gap between the vessel and the stationary inner piece [50]. The shear and 
compression forces experienced by the particles result in the de-agglomeration of larger 
“host” particles (API or excipient) into individual particles, therefore exposing its surfaces to 
the additive material which become deformed or attached onto the surface of the host 
particle [47]. As the additive material is generally smaller and softer than the host particle, it 
is firmly attached onto the surface of the host particle by strong Van der Waals interactions, 
which result in the production of a composite particles with either a discrete or continuous 
surface layer of additive material [50]. In some cases, the increase in temperature generated 
from the high shear and compression forces during the mechanofusion process result in the 
production of composite particles consisting of the additive material fused onto the surface of 
the host particles by strong physical/chemical bonds that further enhances the coating 
process [50]. 
Therefore, the term co-milling in the context of mechanofusion refers to the de-
agglomeration of cohesive host particles into its individual particles, which are subsequently 
fused with a layer of the additive material [50]. The size of the gap between the inner section 
and rotating drum can determine the thickness of the coating on the host particle [50]. The 
gap between the scraper and the wall of the vessel can be controlled, which is used to break 
up or disrupt caking or particle build-up on the walls of the vessel [50]. Typically, the shear 
and compression force does not result in size reduction, but a noticeable change in surface 
morphology and shape of the particles are observed [50]. A schematic representation of the 
mechanofusion is presented in Figure 4 below. 
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Figure 4: A schematic representation of the mechanofusion apparatus. Figure adapted 
from [51]. 
Mechanofusion of excipients or the APIs with additive materials has been investigated by 
several research groups in the field of respiratory research. Specifically, this technique has 
been applied in the production of high dose API formulations and investigated for aerosol 
performance. 
In a study by Begat et al., [49], an investigation into the aerosol performance of APIs 
mechanofused with various additive materials was conducted. A powder mixture consisting 
of 95% w/w API (SS/budesonide) and 5% w/w additive (LEU/Lecithin/MGST) was used to 
generate composite particles [49]. In-vitro aerosol performance was conducted using a low 
resistance Monohaler device operating at 60 L/min. Mechanofusion of the API with MGST 
(5% w/w) resulted in the greatest improvement in powder de-agglomeration, powder 
flowability, and aerosol performance when compared to micronised API. For example, co-
milling with MGST (5% w/w) resulted in a significant reduction in the amount of API 
recovered in the upper stages of a next generation impactor (NGI) and a statistical significant 
increase (p<0.05) in drug recovered in the lower stages (resulting in an increase in fine 
particle fraction from 24.3% for the micronised API to 64.0% for the co-milled material). 
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This was likely due to the reduction in the interaction energy of the contiguous particles, 
which subsequently led to improved fluidisation and de-agglomeration when compared to 
micronised API alone [49].  Further studies investigated aerosol performance in a range of 
API (micronised triamcinolone acetonide, salmeterol xinafoate and SS) after mechanofusion 
with 5% w/w of MGST [52]. In this later study, it was reported that (a) a significant increase 
(p<0.05) in poured and tapped powder densities was recorded after mechanofusion compared 
to micronised API; (b) a significant reduction in powder cohesion values after mechanofusion 
with additive as analysed by powder shear analysis compared to the micronised API; (c) 
improvement in powder de-agglomeration as measured by laser diffraction particle size 
analysis and (d) in vitro aerosol performance of 10 mg samples aerosolised from a Monohaler 
DPI increased significantly in mechanofused samples when compared to the corresponding 
micronised API [52]. 
Further investigation into the aerosol performance of cohesive powders (micronised Lactose 
with a diameter of 3.86 µm) before and after mechanofusion with MGST was conducted by 
Zhou et al., [53]. In this study, a significant improvement in powder flowability from very 
cohesive in micronised lactose, to easy flowing in mechanofused lactose particles 
(characterised using FT4 powder rheometer) was reported. Powder de-agglomeration, as 
measured by laser diffraction at flow rate of 30, 60 and 90 L/min, showed better de-
agglomeration was achieved after mechanofusion as reflected by significantly lower 
measured volumetric mean diameter at all flow rates (p<0.05) compared to micronised 
lactose. Furthermore, a significant reduction in the retention of powder from the device and 
capsule of an RSO1 DPI at the tested flow rates was achieved after mechanofusion with 2% 
w/w MGST. The authors suggested that the changes to the surface composition of lactose 
after mechanofusion was the main contributing factor in the improvement of aerosol 
performance [53]. 
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Investigation into the physico-chemical and surface composition changes after 
mechanofusion of API with additives was investigated by Zhou et al., [54]. Mechanofusion of 
MGST (0.5, 2, 5, 10% w/w MGST) and SS (D50<5 µm) was performed at 5000 rpm for 10 
minutes. Results of the study indicated mechanofusion with 2% w/w MGST resulted in the 
formation of smooth and round composite particles due to surface coverage of the API with 
MGST. An increase in the concentration of MGST (>2% w/w) led to further changes in the 
surface composition of the composite particles, with the formation of overlapping, multi-
layers of MGST (observed under SEM) which led to an increase in surface irregularities and 
roughness of the API. This indicated 2% w/w MGST was the optimal concentration in 
achieving a uniform coating on the surface of API (approx. 10 nm in depth), consistent with 
the results from the surface chemical composition analysis of particles by X-ray 
photoelectron spectroscopy. Furthermore, significant reduction in powder cohesion values, 
improvement in powder flowability (by powder rheology assessment), and powder de-
agglomeration (measured by laser diffraction) after mechanofusion was also observed, 
compared to micronised API.  
This was consistent with other studies which have reported a reduction in surface energy of 
cohesive micronised particles after mechanofusion with MGST, as measured by an 
improvement in powder flowability from powder shear test, improvement in powder de-
agglomeration from particle size shear test, and improvement in emitted dose and FPF% 
from in-vitro aerosol performance analysis [52, 53, 55, 56]. 
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2.4 COMPARISON OF CO-MILLED TECHNIQUES 
 
As demonstrated previously, co-milling of cohesive, fine (<5 µm) powders for inhalation is a 
viable option to overcome the inherent limitations associated with micronised formulations 
(highly cohesive, poor flow, poor dispersion). As co-milling can be performed by either jet 
milling, ball milling, or mechanofusion, a comparison is needed to determine the relative 
effectiveness of each apparatus in terms of the aerosol performance in high dose 
formulations. 
A study by Lakio et al., [21] investigated the delivery of high dose L-arginine (ARG) to the 
lung as a dry powder formulation.  Initially, un-processed ARG was micronised by jet milling 
to a size suitable for inhalation, and subsequently further processed by co-milling with either 
MGST or L-LEU using the ball mill, or mechanofusion. Separately, unprocessed ARG was 
co-milled with MGST (2% w/w) or LEU (20% w/w) by jet mill and then ball milled or 
mechanofused (without further addition of additives). All jet milled and co-milled samples 
resulted in particle size reduction to a size suitable for inhalation (D50<5 µm). However, no 
further size reduction after co-milling with the ball mill or mechanofusion was observed. 
Cohesion between particles was reduced in samples processed with MGST compared to 
LEU. This was likely due to greater surface coverage of MGST, which reduced the surface 
energy of the API by the dry coating process [56, 57]. 
The results of in-vitro aerosol performance analysis of the powder samples from a capsule 
based Monodose DPI (20 mg) were as follows: (a) dose emission from all formulations was 
between 75% and 90%, indicating good fluidisation and dose emission properties; (b) in 
general, batches that were co-milled by the jet mill and mechanofusion had higher FPF% 
compared to ball milled samples (i.e. FPF% values for co-milled by mechanofusion, jet mill, 
and ball mill of 69.51%, 67.02% and 62.1%, respectively). This was likely due to the 
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presence of large agglomerates created by the ball mill apparatus as observed under SEM and 
larger D90 values from laser diffraction analysis. 
In another study [15], high dose formulations were investigated either as a two component 
formulation consisting of the API (apomorphine hydrochloride) with additive material or a 
three component system of API, the excipient (lactose D50<30 µm) and additive material 
(magnesium stearate) processed by either the mechanofusion or jet mill. This resulted in the 
production of four formulations: 1) mixture of the API (26.3% w/w), additive (5% w/w LEU) 
and excipient (68.7% w/w sorbalac) material by mortar mixing; 2) co-milled (by jet mill) of 
the 20% w/w API, additive (5% w/w LEU), excipient (75% w/w sorbolac), 3) co-milled (by 
jet mill) API (95% w/w) additive material (5% w/w LEU), and 4) co-mill (by 
mechanofusion) of additive (5% w/w LEU) with excipient (75% w/w sorbolac), and final 
blend by hand in mortar with 20% w/w API. All formulations had particle size distribution of 
D50<5 µm and were tested using the Aspirair DPI device. Results showed significant 
improvement in the co-milled (by jet mill) formulations, with or without lactose (94% and 
96% FPF(ED), respectively) compared to mechanofused powder (61% FPF%(ED)) and 
mortar mixed formulation (76% FPF%(ED)). This was attributed to the differences in the 
density and the velocity of the aerosol emitted from the device. The mechanofused powder, 
were of a higher density with improved flowability profile and was emitted as a short fast 
bolus which resulted in a significantly higher retention of API in the throat [15]. In 
comparison, the co-milled (by jet mill) samples were lower in density and flowability, which 
improved the amount of de-agglomerated particles released from the DPI and subsequently 
the reduction in throat retention (less than 5% in co–milled (by jet mill) compared to 16-29% 
in mechanofused sample respectively). Such result demonstrates the applicably of co-milling, 
either with or without excipient particles, in enhancing aerosol performance.  
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2.5 CO-MILLING PROCESS IN DPI FORMULATION AND IMPACT 
ON STABILITY PARAMETERS 
 
2.5.1 CHANGES IN MOISTURE SORPTION 
 
Dry powder formulations are generally sensitive to any changes in the relative humidity 
levels during powder processing, transport or storage [58]. Specifically, an increase in the 
relative humidity levels (RH) can have a significant impact on powder stability and aerosol 
performance of the dry powder formulation [58]. The uptake of water molecules is primarily 
depended on the relative humidity of the environment and on the hygroscopicity of the 
materials in the dry powder formulation [59]. Furthermore, micronisation introduces 
amorphous regions to the material, which can lead to significant increases in the uptake of 
water [24]. As the amorphous regions exist at a higher energy state than the crystalline 
material, the uptake of water molecules by the amorphous material will facilitate re-
crystallisation at elevated humidity levels (>75% RH) [60]. The re-crystallisation of the 
amorphous material can lead to the formation of large, dense and cohesive agglomerates 
through solid bridge formation [60-62]. This can lead to significant increase in the particle 
size of the micronised material. For example, micronised albuterol sulphate, was shown to 
increase in particle size from 1.5 µm after micronisation to 3.9 µm after storage at 75% RH 
for 24 hours [60]. Subsequently, agglomeration of fine particles introduces variability in the 
emitted dose from the DPI, a reduction in powder flowability, and reduction in dispersibility 
of the API [25, 63].  
To overcome this issue, co-milling of the API with additive materials have been 
demonstrated to reduce the formation of amorphous regions on the micronised particles and 
subsequently improve the physico-chemical stability of the dry powder formulation. 
Furthermore, the generation of surface coatings on already micronised materials during the 
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co-mill process may reduce moisture sorption and re-crystallisation of amorphous regions 
after storage at elevated humidity level. Previous research have demonstrated the benefits of 
hydrophobic additives to limit or reduce the effect of these storage issues on the API [63, 64]. 
In a study by Lakio et al., [21], the water uptake of composite particles produced from co-
milling a hydroscopic API with either MGST or LEU was investigated using the dynamic 
vapour sorption (DVS) technique. Dry powder formulations of micronised (by jet mill) L-
Arginine (ARG) were co-milled with the additive by either the jet mill, mechanofusion, or 
ball mill apparatus. 
Compared to the moisture uptake of jet milled ARG (20.01%), a reduction in moisture uptake 
was reported after co-milling the API with the additive material (for example jet milled ARG 
- mechanofused with 20% w/w LEU - 15.5%, jet milled ARG - mechanofused with 20% w/w 
MGST-16.5%, and jet milled ARG - co-milled (by jet mill) with 20% w/w LEU – 16.4%, 
respective moisture uptake). Mechanofused formulations were shown to have a lower uptake 
in water molecules, which was likely to be due to a more continuous particle coating of the 
API compared to the jet mill procedure [21]. 
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2.5.2 CHANGES TO THE DRY POWDER PHYSICAL STATE 
 
In addition to the moisture protective effects, co-milling has been shown to protect the API 
from changes to its physical state (whether the particle is amorphous or crystalline). In a 
study by Balani et al., [65], changes to the crystalline structure of SS was investigated after 
co-milling with various crystalline (Lactose, magnesium stearate, Adipic acid (AA)) and 
amorphous (polyvinyl pyrrolidone (PVP)) additives. Co-milling was carried out in a 
planetary ball mill.  SS with lactose at ratios of 1:3 and 1:4, SS with MGST (1:1 ratio) and SS 
with AA (1:1 ratio) were prepared and X-ray diffraction (XRD) used to study crystal 
structure. XRD indicated characteristic peaks for crystalline SS was maintained in all co-
milled samples. The authors suggested the crystalline additives acted as seed crystals to 
induce the re-crystallisation of SS after milling [65]. Furthermore, no changes in crystallinity 
or morphology were observed when the co-milled sample of SS and lactose were stored for 7 
days at 25 °C, 75% RH [65]. 
In a similar study, an investigation into the concentration of PVP (0 to 90% w/w) required to 
maintain the amorphous form of SS upon co-milling by ball mill was investigated [66]. Co-
milled samples of API with PVP (0 to 90% w/w) resulted in amorphous materials. Upon 
storage at 25 °C at 75% RH, differential scanning calorimetry and DVS analysis indicated no 
crystallisation occurred in co-milled samples which contained 33% w/w PVP. Surface 
analysis results indicated the formation of inter-molecular interactions between PVP and the 
API, which was increased with higher PVP content, and the homogenous distribution of PVP 
on the surface of API was likely to stabilise the amorphous phase of the composite particle 
upon storage at high relative humidity [66]. Similar results were reported in a study by Curtin 
et al., [67] who investigated the physical changes when SS was co-milled (by ball mill) with 
three crystalline dicarbocylic acids (glutaric acid (GA)m, Adipic acid (AA)m and Pimelic 
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acid (PA)).  No amorphous material was detected by DVS in Co-milled SS with 50% co-
milling GA formulation, and amorphisation was halved in formulations co-milled with 50% 
co-milling AA and PA. 
 
2.6 CONCLUSIONS 
 
With the expanding interest in the delivery of high dose APIs for the treatment of lung 
disease there is a call for innovative techniques that can produce high efficiency inhalation 
particles which are free from the requirements of large carrier based systems. Carrier free 
formulations can be achieved by co-milling the API with additive materials using either jet 
mill, ball mill or mechanofusion approaches. Improvement in the aerosol performance of co-
milled formulations and physico-chemical stability compared to that achieved by milling 
alone have been reported in this review.  In general, each of the three techniques have pros 
and cons, but all provide viable options for the generation of formulations that can deliver 
high dose API with good dispersibility, flowability and aerosol properties. 
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CHAPTER 3:  INVESTIGATION INTO THE 
MANUFACTURE AND PROPERTIES OF CO-
MILLED FORMULATIONS 
 
INVESTIGATION INTO THE MANUFACTURE AND PROPERTIES OF INHALABLE 
HIGH DOSE DRY POWDERS PRODUCED BY CO-MILLING API AND LACTOSE 
WITH MAGNESIUM STEARATE 
 
3. INTRODUCTION 
The lungs offer several advantages for the delivery of active pharmaceutical ingredients 
(API) compared to other routes of administration. Such advantages include the localized 
treatment of lung diseases and infection, rapid clinical response, and the use of lower doses 
reducing the risk of systemic side effects [1]. Currently, drug delivery to the lungs can be 
achieved by devices including nebulizers, metered dose inhalers (MDIs) and dry powder 
inhalers (DPIs). The DPI is a device which delivers the API as a dry powder, and has several 
advantages compared to the other devices (MDI and nebulizer). These include improved 
stability of the API, simplicity of use, and good patient compliance [2].  
Briefly, the aerosol performance of a dry powder formulation is dependent on: (1) the 
inspiratory flow rate (L/min); (2) the design of the DPI; and (3) the properties of the dry 
powder formulation [3]. A higher inspiratory flow rate (L/min) will generally increase the de-
agglomeration forces generated within the DPI, which subsequently lead to an improvement 
in the amount of micronized API deposited in the lung, as measured by an increase in the fine 
particle fraction of the formulation [4, 5].   
Dry powder inhalers are generally categorized based on the inspiratory flow rate (L/min) to 
achieve a pressure drop of 4 KPa, either as a high (90 L/min), medium (60 L/min), or low 
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resistance (30 L/min) device. In general, high resistance devices are designed to generate 
higher turbulence and subsequently achieve a higher respirable dose of the API [1, 6-8]. 
Finally, as particles between 1-3 µm are generally regarded as the optimal size for deposition 
in the deeper regions of the lung [1, 9], the primary challenge for respiratory scientist is in the 
development of formulations which limit the natural tendency of micronized particles (<5 
µm) to form large, cohesive, agglomerates from inter/intra particulate interactions that cause 
a reduction in the flowability and dispersibility of the formulation [10-13].  
Currently, standard carrier based formulations are used in the delivery of low dose API 
(typically in μg ~100 - 500 μg) for the treatment of inflammatory lung conditions such as 
asthma and chronic obstructive pulmonary disease [3, 4]. A carrier based formulation is an 
interactive mixture consisting of micronized (<5 µm) API attached onto the surface of the 
larger carrier particle (~30 - 90 µm) [14], typically lactose, which improve the flowability and 
dispersibility of low dose dry powder formulations [15-17]. However, the expanding 
application of DPIs in the delivery of high dose API (in mg) for the management of diabetes 
[18], and lung infection [19] has led to new formulation methods tailored for higher dose 
delivery, as the saturation of active sites on the surface of carrier particles in high dose 
formulations lead to fine particle segregation which is detrimental to aerosol performance 
[10].   
Previous reports indicate the delivery of API from a particulate system of similar sizes is a 
more suitable platform in high dose delivery than conventional carrier based dry powder 
formulations [10]. This can be achieved by co-milling the API, additive material, and 
excipient using a jet-mill apparatus. Additive material such as magnesium stearate (MGST) is 
chosen for its anti-adherent, and anti-friction properties which reduce the agglomerate 
strength and enhance the dispersibility and flowability profile of the formulation [10]. The 
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excipient material, typically lactose, is often used to add bulk to the final co-milled 
formulation. 
Co-milling of API with additive material in the production of dry powder formulations has 
gained considerable interest in the field of respiratory drug delivery. Research by Zhou et al., 
[20-22] has demonstrated how improvements in powder flowability, and dispersibility of co-
milled formulations can be achieved by mechanofusion of API with MGST, which is 
basically a dry coating process where the surfaces of the pre-micronized API are coated by a 
thin layer of MGST. Similarly, research by Tay et al., [23] has demonstrated improvements in 
aerosol performance of a dry powder formulation can be achieved by mixing micronized 
API-MGST in a Turbula mixer.  
These methods (mechanofusion/Turbula mix) typically produce final composite particles 
with the surface of the API ‘coated’ by the additive material, without significant changes in 
the particle size of the materials (typically a nano-meter coating by mechanofusion [24]). In 
comparison to the mechanofusion and Turbula mix, co-milling using the jet mill apparatus 
result in the simultaneous production of composite particles, particle size reduction, and 
surface coverage of API by the additive material [25]. This can lead to the generation of 
particles with enhanced powder flowability characteristics and dispersibility properties, as 
demonstrated in the patent by Morton [25] in the co-mill of the API with MGST using the jet 
mill apparatus.  
The aim of this study was to gain a deeper understanding of the interactions between co-
milled formulations of API-MGST-Lactose produced by the jet mill apparatus in terms of 
changes in physico-chemical properties, and its effect on the overall aerosol performance of 
DPI formulations. Initially, experiments sought to understand the effect of MGST% (w/w) 
concentration on the aerosol performance and physico-chemical properties of the co-milled 
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formulations, which would lead to a second set of experiments to understand the effect of 
API% (w/w) concentration on both physico-chemical properties and aerosol performance for 
high dose delivery. The effect of an increase in capsule fill mass of the DPI on the overall 
aerosol performance of the co-milled formulations was also investigated. 
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3.1 MATERIALS AND METHODS 
 
3.1.1   MATERIALS 
 
Lactose (InhaLac®, Meggle group, Germany), API (Beclomethasone Dipropionate – BDP, 
Farmabios S.R.L., Italy) and magnesium stearate (MGST, Peter Greven Group, Germany) 
were used as received. Reagents used for HPLC analysis were of chromatography quality and 
were supplied by Sigma (Sydney, NSW, Australia). Purified water by reverse osmosis (Milli-
Q, Sydney, Australia) was used throughout the experiments. 
3.1.2   PREPARATION OF CO-MILLED BDP/MGST/LACTOSE 
FORMULATION 
 
To investigate the optimal concentration of MGST% (w/w) on co-milled formulations, five 
10 g sample blends (Batch 1-5) of BDP/MGST/Lactose were prepared in the ratio presented 
in (Table I). Initially samples were mixed using a shaker-Mixer (Hexagon Ltd, Model 
Alphie-03) for 60 minutes at 32 rpm using a steel container (Radius 1.2 cm, height 4 cm, 
volume 18.1 cm3). To investigate the effect of an increase in BDP concentration on aerosol 
performance in co-milled formulations, another four batches (Batch 6-9) were prepared 
(Table II) following the same method as above. In all samples, lactose was used as a bulking 
agent to achieve a final powder weight of 100% (w/w). Each sample was then co-milled by 
one pass through a jet-mill (Labo Mill Micronization Equipment FPS 0447, Italy), at 1 g/min 
feed rate, 7 Bar injection pressure, and 7 Bar grinding pressure at controlled room humidity 
and temperature (50% relative humidity (RH), 20C). After co-milling via the jet-mill, 
samples were stored in glass containers at controlled temperature and humidity (50% RH, 
20C). All samples were stored for a minimum of 24 hours prior to analysis. 
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Components 
(% w/w) 
BATCH 1  
 
BATCH 2 BATCH 3  BATCH 4  BATCH 5 
BDP  1 1 1 1 1 
MGST  0 1 2.5 5 7.5 
LACTOSE  99 98 96.5 94 91.5 
Table I: Composition of the jet-milled BDP/MGST/Lactose batches to investigate the effect 
of MGST% (w/w) on aerosol performance. 
 
 
 
Table II: Composition of the jet-milled BDP/MGST/Lactose batches to investigate the effect 
of BDP% (w/w) on aerosol performance. 
 
 
 
 
 
 
 
 
 
 
Components 
(% w/w) 
BATCH 6 BATCH 7  BATCH 8 BATCH 9 
BDP  10 20 30 40 
MGST  5 5 5 5 
LACTOSE  85 75 65 55 
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3.1.3   SCANNING ELECTRON MICROSCOPY (SEM) 
 
Scanning electron micrographs of all the blend samples were conducted using a scanning 
electron microscope (SEM) (JEOL-JCM 6000 NeoScope Benchtop SEM, Tokyo, Japan) 
under a range of magnifications using 15 kV accelerating voltage. Prior to analysis, samples 
were mounted on adhesive carbon tape (pre-mounted on aluminum stubs), and coated twice 
with gold to a thickness of approximately 15 nm using a sputter coater (BAL-TEC SCD 005, 
Tokyo, Japan). 
 
3.1.4   PARTICLE SIZE ANALYSIS BY LASER DIFFRACTION 
 
Particle size analysis for each sample blend was determined by laser diffraction using a 
Mastersizer 3000 (Malvern, UK) equipped with Aero S dry powder dispersion unit, dry 
sample tray and hopper. Approximately 50 mg powder samples were weighed and dispersed 
in air at a shear pressure of 3 Bar. Size distributions were reported as D10, D50, and D90 
cumulative particle undersize values (e.g for D50 = 8.6 μm, 50% of the tested particle size in 
the sample is less than 8.6 μm).  Measurements were taken from three replicates of each 
sample at a default refractive index (RI: 1.52) [23] and analyzed using the Malvern 
Mastersizer software (Version 3.30). 
3.1.5   UNIFORMITY OF CONTENT 
 
Each sample blend was tested for uniformity of content according to the British 
Pharmacopoeia 2016 [26]. From each blend, ten random samples of 10 ± 1 mg were assayed 
and diluted in mobile phase (80% methanol and 20% water v/v). Analysis of BDP content 
was determined by high performance liquid chromatography (HPLC). The % BDP recovery 
78 
 
from each sample was determined from dividing the BDP content (from HPLC analysis) by 
the calculated amount of BDP in each sample. 
3.1.6   PARTICLE SIZE SHEAR PRESSURE ANALYSIS 
 
Particle size shear pressure profiles of the sample blends after jet-milling were determined by 
laser diffraction using the Mastersizer 3000 (Malvern, UK) as reported previously.  
Increasing shear pressures (0.5, 1, 2, 3 and 4 Bar, respectively) were used to assess the 
strengths of the agglomerates [23]. Approximately 50 mg powder samples were weighed and 
fed through the hopper into the dry sample tray. Measurements were taken from three 
replicates of each sample with the RI set at 1.52 [23]. Sample data was processed and 
analyzed using the Malvern Mastersizer software (Version 3.30). 
3.1.7   X-RAY PHOTOELECTRON SPECTROSCOPY (XPS) 
 
Chemical composition of the samples was analyzed using X-ray photoelectron spectroscopy 
analysis (XPS) (Specs, Surface Nano Analysis, Berlin, Germany) equipped with Al X-ray 
source with monochromator operating at 200 W, a hemispherical analyzer and a line delay 
detector with 9 channels. A small amount of the powder sample was filled into powder 
sample holders. Survey spectra were acquired for binding energies in the range from 0 to 
1200 eV using 30 eV pass energy. C 1s, O 1s and N 1s region spectra were acquired at a pass 
energy of 23 eV with 10 scans to obtain high spectral resolution and low noise level. The 
peaks were fitted with a sum of Gauss function with Shirley background using Marquardt-
Levenberg fitting procedure of CasaXPS. The peaks were quantified using relative sensitivity 
factors. 
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3.1.8   IN VITRO AEROSOL PERFORMANCE STUDIES 
The in-vitro aerosol performance of each sample blend was determined using the abbreviated 
impactor apparatus (Fast Screening Impactor, FSI, Copley, UK). The FSI is a two stage 
impactor consisting of a pre-separator stage which contains an insert with a central cup for 
the collection of the non-inhalable bolus, and a lower stage with an aerodynamic cut off 
diameter of 5 µm, when operating at a flow rate of 60 L/min. Particles less than 5 µm are 
collected in the fine particle chamber on a glass fibre filter which is located in an external 
filter holder with quick release latches.  
Briefly, the pre-separator is assembled as follows: the insert is placed into the pre-separator 
base, the pre-separator base is fitted to the inlet of the impactor, 15 mL of HPLC mobile 
phase is added to the central cup of the pre-separator insert, and the pre-separator body is 
assembled on top of the pre-separator base and closed by the 2 latches. The induction port is 
fitted to the pre-separator inlet and a mouthpiece adapter is fitted to the end of the induction 
port. The FSI uses the same induction port as the Apparatus E (Copley, Nottinghamshire, 
UK). The FSI was connected to a rotary vein pump (Westech Scientific Instruments, 
Bedfordshire, UK) and the flow rate adjusted to 60 L/min using a calibrated flow meter 
(Model 4040, TSI Model Instruments, Germany). 
The RSO1 (PlastiApe, SPA, Italy) high resistance dry powder inhaler, was used for assessing 
the aerosol performances of the sample blends. Briefly, different amounts of powder sample 
(10, 20, and 30 mg) was loaded into size 3 hydroxypropyl methylcellulose (HPMC) capsules 
(Capsugel, Peapack, New Jersey, USA), inserted into the DPI and the capsule pierced. The 
inhaler was inserted into custom manufactured silicon moulded mouthpieces attached to the 
FSI and actuated at an air-flow set at 60 L/min for 4 seconds. After actuation, the inhaler 
device, capsule, mouthpiece, throat, pre-separator and filter paper were washed with mobile 
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phase and collected into individual volumetric flasks. Each sample was filtered with a 0.22 
µm Nylon filter (Aireka Cells, 13 mm diameter, 0.22 µm pore size, Hong Kong) to remove 
any remaining lactose and MGST before determination of the BDP content by HPLC. All 
experiments were conducted at 20 °C ± 2 °C and 50% ± 10% RH in triplicate. 
For the purpose of this study the aerosolization parameters were defined as follows: 
recovered dose (RD): the amount of BDP collected from the DPI, capsule, mouthpiece, 
throat, pre-separator and the filter from the fine particle chamber; emitted dose % (ED): the 
amount of BDP recovered from the mouthpiece, throat, pre-separator and the filter from the 
fine particle chamber as a percentage of the RD; Dispersibility (%, representing the powder 
de-agglomeration efficiency): the amount of BDP recovered from the fine particle chamber as 
a percentage of the ED; The fine particle dose (FPD) is the amount of fine BDP particles, less 
than 5 µm in size, collected on the filter in the fine particle chamber of the FSI. 
 
 
3.1.9   CHEMICAL ANALYSIS BY HPLC 
 
Quantification of assayed samples containing BDP was performed using high performance 
liquid chromatography. A Shimadzu Prominence HPLC system was utilised for all chemical 
quantification and consisted of SPD-20A UV-Vis detector, LC-20AT solvent delivery unit, 
SIL-20A HT Autosampler (Shimadzu Corporation, Japan). The pump flow rate was set to 1.0 
mL/min and the sample injection volume was 100 µl. A wavelength of 243 nm was used for 
detection of BDP and a NovaPak C18 column (5 µm, 150 mm x 3.9 mm) (Waters 
Corporation, Milford Massachusetts, USA) used for separation. The mobile phase was 
methanol, water (80:20% v/v) filtered and degassed using a 0.45 µm membrane filter 
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(Millipore, Country Cork, Ireland). Linearity was obtained between 0.05-100 µg/mL (R2 = 
0.999) with a retention time of ~7.5 min. 
3.1.1.1   STATISTICAL ANALYSIS 
 
Statistical analysis was performed using One-Way Analysis of Variance (ANOVA) (SPSS, 
USA) with Tukey post hoc test, and probability values of (p) <0.05 considered as statistically 
significant. 
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3.2   RESULTS AND DISCUSSION 
 
3.2.1   SCANNING ELECTRON MICROSCOPY 
 
Changes in particle size, agglomerate structure, and particle morphology of the materials, 
before and after processing by jet-milling, were investigated to determine the effect of such 
changes on the uniformity of content and aerosol performance results.  
SEM images of the un-processed lactose revealed its granulated structure, with the presence 
of various surface cracks and crevices produced from the fusion of smaller sub-units of 
lactose particles (Figure 1A). Structural changes on the lactose surface were observed after 
micronization, from the large granulated structure to a heterogeneous mixture of particles 
with various shapes and sizes (Figure 1B). As the lactose particles were subjected to only one 
pass through the jet-mill, a mixture of particle sizes was produced from large (>25 µm) to 
medium (<25 µm) and fine particles (<10 µm). The reduction in the particle size of 
micronized lactose led to an increase in the particle surface area which increases the number 
of active sites for the attachment of fine particles (Lactose/MGST or BDP) compared to the 
large un-micronized lactose carrier [25].  
MGST appeared as corrugated, layered structures with no definite shape or size. Jet-milled 
MSGT appeared as de-agglomerated individual micronized particles (<5 µm) (Figure 1C and 
D, respectively). While an extensive investigation into the chemical and physical properties 
of MGST was beyond the scope of this manuscript, results from previous research have 
indicated significant batch to batch variability exists in terms of particle size, surface area, 
moisture content, and crystalline state [27-29], which can lead to differences in the lubricant 
properties of MGST and subsequently cause differences in the flowability, and solubility of 
the final formulation [30, 31]. Batch variability is likely contributed by differences in the 
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manufacturing conditions (such as temperature and relative humidity) which can lead to the 
production of commercial grade MGST with varying ratios of the hydrate state [30], or from 
differences in the purity of the raw materials used. Therefore, the results presented in this 
manuscript apply to the batch of MGST as provided by the specific supplier. 
BDP was shown to have a flaky/layered particle morphology (Figure 1E) which became 
irregular plate-like, and more spherical in shape once micronized (Figure 1F).   
A mixture of particle sizes and morphologies were observed from the co-milled formulations 
(Figure 1G to O). The variation was likely contributed by the lactose particles as it formed 
the bulk of the co-milled formulation, which exhibited significant changes in particle size and 
morphology after micronization. The larger lactose particles acted as carriers for the 
attachment of micronized MGST/BDP/Lactose particles. Furthermore, agglomerates of fine 
particles were observed, which was likely the result of inter/intra particle interactions. 
Therefore, co-milled formulations consisted of a particulate system of: (1) Fine particles of 
either BDP/MGST/Lactose attached onto the surface of larger lactose particles and, (2) Fine 
particle agglomerates that were either attached or detached from the large lactose particle. 
Differences in the agglomerate structure was observed from the co-milled formulations with 
different concentrations of MGST (Batches 1-5). In Batch 1 (Without MGST), a network of 
large and dense agglomerates of BDP and lactose particles was observed (Figure 1G). The 
agglomerates were either attached on the lactose carrier (> 25 µm) or formed multiplets of 
fine particles detached from the carrier.  
Co-milling with different concentrations of MGST (Batches 2-5) led to the simultaneous 
micronization and distribution of fine, de-agglomerated particles of MGST that were likely 
attached onto the surfaces of the micronized BDP and lactose particles. Surface coverage 
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provided a physical barrier which increased the separation distance between the adjacent 
micronized particles, and was likely to have led to the reduction in the number of inter/intra 
particulate interactions. This was observed under SEM in the formation of distinct fine 
particles that were in a loose agglomerate arrangement (Figure 1H to J). 
The increase in MGST% (w/w) from 5 to 7.5% (w/w) led to structural changes in the 
agglomerates, observed under SEM images for the latter formulation as the increase in the 
number of large, multi-layered, dense agglomerates of fine particles (Figure 1K). This was 
likely due to the saturation of the active binding sites on the surface of the larger lactose 
particle by the increase in the number of fine MGST particles, which likely led to the 
segregation of micronized particles, and subsequently the formation of dense agglomerates 
from inter/intra particle interactions (Figure 1K).  
SEM images of co-milled formulations with different concentrations of BDP (Batches 6-9) 
showed an increase in the size and number of agglomerates was observed as the BDP% 
(w/w) was increased from 10 to 40% (w/w) (Figure 1L to O), likely contributed by the 
increased number of inter/intra particulate interactions between BDP particles. Furthermore, 
changes in the agglomerate structure was observed, from a loose network of interacting 
particles in the 1 to 10% (w/w) BDP formulations, to a dense, compact agglomerate structure 
in the 20 to 40% BDP (w/w) formulations (Figure 1L to O) respectively.  
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Figure 1: Scanning electron microscopy of: (A) Lactose, (B) jet-milled Lactose, (C) MGST, 
(D) jet-milled MGST, (E) BDP, (F) jet-milled BDP, (G) Batch 1, (H) Batch 2, (I) Batch 3, (J) 
Batch 4, (K) Batch 5, (L) Batch 6, (M) Batch 7, (N) Batch 8, (O) Batch 9. 
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3.2.2   PARTICLE SIZE BY LASER DIFFRACTION 
 
For all samples, particle size reduction for inhalation was achieved after micronization of the 
materials by jet-milling (Figure 2A). For example, the D50 of jet-milled materials were: 
Lactose 5.32 µm ± 0.2, BDP = 1.64 µm ± 0.3, MGST = 2.55 µm ± 0.5, respectively. 
Particle size analysis of the co-milled formulations with different % (w/w) of MGST indicate 
micronization to a size suitable for inhalation was achieved in all formulations (D50 <5 µm, 
Figure 2B). 
Particle size analysis were consistent with the observations made using SEM, with an 
increase in the agglomerate size as the BDP concentration in the co-milled formulations was 
increased (Figure 1L to O). For example, the particle size distribution of 1% BDP was D90 
<10 µm of fine particles, and a D50 <5 µm of micronized particles. However, an increase in 
the BDP to 40% (w/w) led to an increase in D90 >10 µm (Figure 2C), likely due to the 
presence of large agglomerates that were formed from the interaction between cohesive BDP 
particles post micronization.  
Therefore, the concentration of MGST% (w/w) and BDP% (w/w) was likely to have caused 
changes in uniformity of content of BDP, which could have introduced variability in the 
distribution of BDP within the formulation and consequently cause an impact on aerosol 
performance.  
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Figure 2: Particle size analysis of: A)  Lactose, MGST and BDP before and after jet-Milling 
(Y-axis log10 scale), B): co-milled formulations with different concentration of MGST% 
(w/w) (Batch 1-5) and C) different concentrations of BDP% (w/w) (Batch 4, 6-9 respectively) 
(n=3,  StDev). 
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3.2.3   UNIFORMITY OF CONTENT OF CO-MILLED SAMPLE BLENDS 
 
Changes in the uniformity of BDP in the co-milled formulations was likely to have occurred 
with changes in the concentration of MGST% (w/w) and BDP% (w/w), respectively.  
Results from the first four batches (0 to 5% MGST w/w) were within the acceptable 
pharmacopoeia range (not more than one individual sample was outside the limits of 85% to 
115% of the average content and none outside the limits of 75% to 125% of the average 
content) [26] (Figure 3A). This was likely attributed to the jet-milling procedure which led to 
the simultaneous mix and micronization of the materials that ensured an even distribution of 
BDP was achieved, either on the surface of larger lactose particles or onto surfaces of 
micronized particles in the formation of agglomerates.  
The attachment of micronized API onto larger lactose particles has been demonstrated to 
improve the uniformity of API content in the formulation, as an interactive mixture ensures 
the uniform distribution of API is achieved by minimising the number of inter/intra 
particulate interactions between micronized particles (<5 µm), which can lead to variability in 
uniformity of content due to the formation of agglomerates [10, 32, 33].  
Failure in uniformity of content was observed with an increase in MGST concentration from 
5 to 7.5% (w/w), as more than three samples were outside the acceptable pharmacopeia limits 
(Figure 3A). This was likely due to an increase in the surface coverage and ultimately 
saturation of the lactose active sites from the electrostatic forces of attraction between 
Lactose-MGST particles.  
As reported previously, the greater the attraction between two sets of particles the larger the 
difference in the magnitude of electrostatic charges between particles [34]. In our case, 
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lactose being electro-negative charged will experience a strong electrostatic attraction with 
the electro-positive charged MGST. Therefore, the attraction between opposite charged 
particles (MGST–Lactose) likely contributed to the saturation of the binding sites on lactose 
particles with the increase in MGST concentration, as observed under SEM at 7.5% MGST 
(w/w) (Figure 1K). The saturation of active sites likely led to the segregation and 
agglomeration of micronized particles (BDP/Lactose/MGST) which contributed to the 
variability in the uniformity of content of BDP as the MGST concentration was increased to 
7.5% (w/w).   
In addition, previous research by Staniforth et al.,[35] have reported the ability of MGST to 
dislodge API bound to the surfaces of lactose carriers, which would further increase the 
segregation of micronized BDP particles and the increase in the formation of cohesive 
agglomerates. Furthermore, the results are consistent with previous reports of the reduction in 
the uniformity of content of the API in dry powder formulations with the increase in MGST% 
(w/w) concentration [36].  
The uniformity of content for the batches of powder used to investigate the effect of BDP 
concentration (Figure 3B) showed results were generally within the acceptable limits, with 
failure in uniformity at a content of 40% BDP (w/w). This was likely due to the increased 
formation of large, dense cohesive agglomerates, from the interaction between cohesive BDP 
particles, as the concentration of BDP was increased in the formulation.  
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Figure 3: A) Uniformity of content for the co-milled (Batch 1-5) – effect of MGST% (w/w) 
(n= 3,  StDev), B) Uniformity of content for the co-milled formulations (Batch 4, 6-9 
respectively) – effect of BDP% (w/w) (n= 3,  StDev). 
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3.2.4   PARTICLE SIZE SHEAR PROFILE 
 
The physico-chemical property of the formulation is one of the factors which can have an 
impact on the aerosol performance. In particular, the rate of powder de-agglomeration and 
flowability are primarily dependent on the extent of the cohesive/adhesive forces between 
particles (e.g. Van der Waals, electrostatic, capillary, mechanical interlocking and friction 
forces) [6]. Therefore, as micronized particles have a tendency to form highly cohesive 
agglomerates from inter/intra particulate interactions, the energy supplied in the form of 
inspiration must be sufficient to overcome the interactions between particles, as the extent of 
powder de-agglomeration affects the fraction of the inhaled powder that is within the 
respirable range [7, 37]. To determine the extent in the adhesive/cohesive forces of the co-
milled formulations, particle size shear pressure analysis was performed by subjecting the 
powder to increasing shear pressure (0.5, 1, 2, 3, and 4 Bar) in the powder dispersion unit of 
the Mastersizer and measuring the particle size (D50) by laser diffraction at each pressure 
setting.  
At the shear pressure setting of 0.5 Bar, de-agglomeration of the 1% BDP/99% Lactose co-
milled formulation was not achieved, as indicated by the high particle size result (D50 = 8.45 
µm, Figure 4A). The increase in pressure (from 0.5 to 4 Bar) provided sufficient energy for 
further de-agglomeration, as indicated by the reduction in particle size. De-agglomeration 
was achieved at shear pressure setting of 2 Bar (D50 = 5.02 µm).  
For all co-milled formulations containing MGST, de-agglomeration was achieved at a lower 
shear pressure of approximately 1 Bar (Figure 4A). The optimal concentration of MGST was 
5% (w/w), as further increase in MGST concentration was not associated with further 
reduction in particle size shear pressure profile. 
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Improvement in powder de-agglomeration with the addition of MGST was likely associated 
with changes in the agglomerate strength and structure; from dense, and cohesive 
agglomerates in the co-milled formulation without MGST compared to the loose agglomerate 
structure when MGST was included in the co-milling process; as observed under SEM 
(Figure 1G to J), and consistent with particle size shear analysis. This was likely due to the 
mechanical processes involved in the manufacture of the formulations (jet-milling and 
mixing) that led to the distribution of sheared and delaminated fine particles of MGST 
adsorbed onto the surfaces of the API and lactose particles which reduced the extend of 
inter/intra particulate interactions between micronized particles. 
Particle size shear analysis was performed on the co-milled formulations with various 
concentrations of BDP% (w/w) (Figure 4B). From the results, co-milled formulations with a 
higher concentration of BDP% (w/w) (>10%) required a higher shear pressure to achieve 
powder de-agglomeration. For example, formulations with 1 and 10% BDP (w/w) achieved 
de-agglomeration at 1 Bar shear pressure, while an increase in concentration from 20 to 40% 
BDP (w/w) required a shear pressure of 2 Bar to achieve de-agglomeration (Figure 4B). This 
suggest changes in the tensile strength of the agglomerates occurred from an increase in 
BDP% (w/w) concentration in the co-milled formulation.  
The following equation is used to analyze the changes associated with the tensile strength of 
an agglomerate [38]:  
                                                          σ  = 
15.6 ϕ⁴W   
𝑑
 
where σ is the tensile strength of the agglomerate, is the packing fraction (volume of 
particles/volume of aggregate), W is the work of adhesion and d is the particle diameter.  
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From the equation, formulations with a higher percentage of micronized particles (<5 µm) are 
likely to form agglomerates with higher tensile strength. Therefore, as the concentration of 
BDP% (w/w) was increased in co-milled formulations, an increase in the tensile strength of 
the agglomerates would occur, due to the increased interaction between micronized BDP 
particles. Images from SEM indicated such changes in the structure of the agglomerates 
occurred; from the loose network of agglomerates observable between 1 to 10% BDP (w/w) 
to the formation of densely packed, cohesive agglomerates with an increase in BDP from 20 
to 40% (w/w) (Figure 1L to O).  
Furthermore, an increase in the tensile strength will generally lead to the reduction in powder 
de-agglomeration efficiency, as a result of the increase in adhesive/cohesive interactions 
between particles [38]. This was observed in the particle size shear analysis (Figure 4B), 
which indicated the increase in BDP% (w/w) (from 20 to 40%) led to a reduction in de-
agglomeration efficiency, compared to 1 and 10% BDP (w/w), respectively.  
The results are consistent with previously reported data where agglomerate structures and 
aerosol performance of powder mixtures consisting of micronized salbutamol sulphate and 
lactose in various ratios (1:1 up to 1:8 w/w) were investigated [39]. At the 1:1 (w/w) ratio, 
SEM imaging revealed agglomerate structures which were compact, in contrast to loose 
agglomerates in the 1:8 ratio formulation, attributed to an increase in the separation distance 
between cohesive API particles due to the increase in the concentration of lactose particles. 
This subsequently resulted in an improvement in aerosol performance in the formulation with 
a higher concentration of lactose particles [39]. Similar results have also reported by other 
researchers [23, 40-42].  
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Figure 4: Particle size shear pressure analysis of A) co-milled formulations with different 
concentrations of MGST% (w/w) (Batch 1-5) and, B) co-milled formulation with different 
concentrations of BDP% (w/w) (Batch 4, 6-9 respectively) (n=3,  StDev).    
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3.2.5   XPS 
 
XPS was used to detect the chemical properties of particles at a depth of approximately 5-10 
nm, which represents the outermost surface layer of the particles [43, 44].  The relative 
atomic ratio of Mg for pure MGST (100% MGST sample) was consistent with the theoretical 
value of MGST, which indicate the detection of Mg from the co-milled samples were due to 
the surface coverage by MGST [45] (Table III). The elemental composition ratio for co-
milled 0% MGST was consistent for the theoretical value of lactose [45], and with the 
expected result of no detection of Mg from this sample.  
An increase in the Mg and a decrease in the O ratio respectively was observed with the 
increase in MGST concentration from the co-milled samples (Table III), which suggest an 
increase in surface coverage of micronized particles by MGST occurred. The increased 
surface coverage was likely responsible for the improvement in powder de-agglomeration, 
and in vitro aerosol performance by the reduction in inter/intra particulate interactions, as 
reported in this manuscript.  
The Mg ratio of co-milled 7.5% (w/w) sample approached similar value to that of 100% 
MGST (w/w), which suggest the outer surface of micronized particles were likely extensively 
coated by MGST (Table III). This was consistent with the agglomerate structure of the co-
milled 7.5% MGST (w/w) formulation as observed under SEM (Figure 1K); agglomerates 
with multi-laminar layers of fine particles were likely formed from the excessive surface 
coverage of MGST on micronized particles. Additionally, this led to an increase in the 
surface roughness of coated particles, which was likely to have promoted particle inter-
locking that caused a reduction in particle de-agglomeration efficiency, and consequently the 
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reduction in aerosol performance as demonstrated from the results in the manuscript and 
consistent with the result reported previously [22]. 
In the second group, co-milled formulations with increased concentration of BDP (1 to 40% 
w/w) at the set 5% MGST (w/w) was produced and analyzed for surface elemental 
composition by XPS. Generally, the Mg and O ratio decreased with the increase in BDP 
concentration of the co-milled formulations (Table III). Therefore, the reduction in the extent 
of surface coating of particles by MGST resulted in the subsequent increase interaction 
between cohesive micronized BDP particles, and this was likely to have caused the reduction 
in de-agglomeration efficiency as measured by in-vitro aerosol performance and particle size 
shear analysis. 
 
Table III: Surface elemental composition of powder samples measured by XPS. The 
elemental compositions are listed as the relative atomic ratio to the total carbon concentration 
(atomic ratios O/C and Mg/C, respectively). 
 
 
 
                                                                    Relative Atomic Ratio 
                                                Element                                               Element 
Sample                                        O                                                       Mg 
100% MGST                               0.12                                                   0.028       
Co milled 0% MGST                  0.86                                                   0.0     
Co milled 1% MGST                  0.63                                                   0.0078  
Co milled 2.5% MGST               0.48                                                   0.014    
Co milled 5% MGST                  0.36                                                   0.020 
Co milled 7.5% MGST               0.26                                                   0.024 
 
Co milled 1% BDP                     0.36                                                   0.020 
Co milled 10% BDP                   0.30                                                   0.017  
Co milled 20% BDP                   0.31                                                   0.015 
Co milled 30% BDP                   0.28                                                   0.014 
Co milled 40% BDP                   0.26                                                   0.013 
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3.2.6   IN VITRO AEROSOL PERFORMANCE – THE EFFECT OF MGST% 
W/W AND BDP% W/W ON AEROSOL PERFORMANCE 
 
An aerosol dispersion study was conducted to identify the optimal concentration of MGST 
(% w/w) in the delivery of API from co-milled formulations. The fill mass, which is the 
amount of powder weighed (10 mg, 20 mg, 30 mg) into the size 3 HPMC capsule of the 
RSO1, was investigated as a means to deliver higher doses of the API. Specifically, aerosol 
performance was evaluated in terms of emitted dose (%), dispersibility (%) and the recovery 
(%) of BDP from each stage (capsule, device, throat, pre-separator and filter) as a percentage 
to the recovered dose.  
A general increase in emitted dose was associated with an increase in MGST concentration 
(Table IV). The greatest difference in emitted dose (%) performance was observed between 0 
and 5% MGST (w/w), for example at 10 mg fill mass, the emitted dose increased from 71.3% 
to 84.5%, respectively (p <0.05). No significant difference was observed between 5 and 7.5% 
MGST (w/w).  
Improvement in dose emission was likely due to the surface coverage on the inner surfaces of 
the capsule and device by MGST during inhalation, which subsequently led to the reduction 
in the interaction and retention of BDP from the capsule and device.  
Differences in the dispersibility (%) between the co-milled formulations (Table IV), was 
likely due to differences in the de-agglomeration efficiency of the formulations, as reflected 
in the recovery (%) of BDP from the throat, pre-separator stage, and the fine particle chamber 
of the FSI (Table IV).  Generally, the addition of MGST reduced the recovery (%) of BDP in 
the throat and pre-separator, with the greatest reduction observed between 0 and 5% MGST 
(w/w) respectively. Therefore, 5% MGST (w/w) was required for the production of highly 
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dispersible co-milled formulation, as observed from particle size shear analysis (Figure 4A) 
and in vitro aerosol performance analysis (Table IV).  
An increase in MGST concentration from 5 to 7.5% (w/w) resulted in a significant reduction 
(p <0.05) in dispersibility (%) (Table IV), due to the higher BDP recovery (%) in the throat 
and pre-separator (Table IV). This suggest 5% (w/w) of MGST was the optimal concentration 
in the production of highly dispersible co-milled formulation, due to changes in the cohesive-
adhesive properties as reported in particle size shear results (Figure 4A). Furthermore, the 
segregation of micronized particles as observed from the uniformity of content (Figure 3A) 
and SEM (Figure 1K) likely contributed to the reduction in dispersibility for the 7.5% MGST 
(w/w) formulation (Table IV). These results are consistent with previous reports of a 
reduction in dispersibility (%) of the API with an increase in the concentration above the 
optimal level of the additive material (Leucine) in the dry powder formulation, with a 
reduction in the respirable fraction of budesonide from 59.1% to 54.9% at 5 and 10 % L-
leucine (w/w) concentration, respectively [46].  
Generally, the concentration of BDP% (w/w) had no significant impact on the emitted dose 
(%) of the co-milled formulations (Table V) at the tested fill mass. However, increase in fill 
mass had a significant impact on the emitted dose, as discussed in the next section.  
A general increase in the BDP recovery (%) from the throat and pre-separator was observed 
with an increase in BDP % (w/w) (Table V), likely due to the increase in agglomerate 
strength and reduction in de-agglomeration efficiency as observed from SEM and particle 
size shear analysis respectively. This led to the impaction and retention of agglomerates on 
the inner walls of the throat, and the retention of agglomerates larger than 5 µm in size from 
the pre-separator during in-vitro aerosol performance (Table V). Consequently, the increased 
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retention of BDP in the throat and pre-separator led to a general reduction in the dispersibility 
(%).   
3.2.7   IN VITRO AEROSOL PERFORMANCE – THE EFFECT OF FILL 
MASS 
 
In general, an increase in fill mass from 10 to 30 mg led to significance differences (p <0.05) 
in the emitted dose performance of the formulations. For example, in co-milled formulations 
with higher MGST concentrations (5 % MGST (w/w), a significant reduction in emitted dose 
was observed, while at lower MGST concentration (1% and 2.5% (w/w), a significant 
increase in emitted dose was observed between 10 and 30mg fill mass (Table IV). This was 
likely associated with differences in particle release characteristics, such as plume force 
velocity and powder de-agglomeration efficiency of the formulations, which would require 
further investigation. Emitted dose of batches 6-9 were in the range of 82.8 to 84.7% at the 
tested fill mass of 10 to 30 mg (Table V), and significant reduction was in general observed 
between 10mg and 30mg fill mass.  
In addition to the emitted dose, the increase in fill mass generally caused a significant 
reduction in the dispersibility of the formulations (batch 1-9) (p <0.05) (Table IV and V). The 
primary mechanism for powder de-agglomeration of the RSO1 is the spinning/rotation of the 
capsule during inhalation, and an increase in the capsule fill mass would require higher 
energy, in the form of a higher inspiratory flow rate, to maintain equivalent capsule rotation 
for powder dispersion performance relative to that of a lower fill mass, as previously 
demonstrated by Chew et al., [47].  
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Table IV: Recovery (%) of BDP from each stage of the FSI and DPI (capsule, DPI, throat, 
pre-separator) as a percentage to recovered dose from batch 1-5, at 10 mg to 30 mg capsule 
fill mass using the RSO1 (n=3,  StDev). 
 
 
 
 
 
 
 
 
 0% MGST 
(Batch 1) 
1% MGST 
(Batch 2) 
2.5% MGST 
(Batch 3) 
5% MGST 
(Batch 4) 
7.5%MGST 
(Batch 5) 
Fill mass (mg) 10 
 
20 
 
30 
 
10 
 
20 30 10 20 30 10 20 30 10 20 30 
Capsule 9.4
± 
0.2 
4.5
± 
0.2 
3.8
± 
0.2 
9.0
± 
1.0 
4.1 
± 
0.1 
3.1 
± 
0.3 
4.4
± 
0.8 
4.0
± 
0.6 
2.9
± 
0.3 
3.3
± 
0.1 
2.7
± 
0.4 
1.9
± 
0.5 
2.9
± 
0.2 
2.4
± 
0.2 
1.9
± 
0.2 
Device 19.
6 ± 
0.2 
24.
9 ± 
0.2 
26.
1 ± 
0.7 
17.
2 ± 
0.8 
19.
6 ± 
0.4 
19.
4 ± 
0.4 
15.
1 ± 
0.6 
17.
6 ± 
0.5 
18.
1 ± 
0.2 
10.
5 ± 
0.1 
12.
8 ± 
0.8 
14.
5 ± 
0.5 
9.5
± 
0.2 
13.
3 ± 
0.5 
15.
1 ± 
0.3 
Emitted dose  71.
3 ± 
0.5 
70.
1 ± 
0.5 
70.
1 ± 
0.2 
73.
7 ± 
1.1 
76.
5 ± 
0.6 
76.
8 ± 
0.7 
75.
2 ± 
0.8 
78.
2 ± 
0.9 
78.
4 ± 
0.4 
84.
5 ± 
0.2 
84.
2 ± 
0.4 
83.
6 ± 
0.3 
84.
1 ± 
0.4 
84.
1 ± 
0.5 
83.
4 ± 
0.5 
Throat 16.
8 ± 
0.2 
18.
6 ± 
0.6 
21.
7 ± 
0.3 
13.
2 ± 
0.7 
17.
7 ± 
1.1 
18.
8 ± 
0.4 
11.
2 ± 
0.3 
16.
2 ± 
0.6 
18.
8 ± 
0.2 
11.
4 ± 
0.1 
13.
8 ± 
0.6 
15.
8 ± 
0.5 
11.
2 ± 
0.5 
16.
4 ± 
0.7 
18.
3 ± 
0.6 
Pre-separator 23.
7 ± 
0.8 
25.
7 ± 
0.5 
28.
2 ± 
0.7 
21.
8 ± 
1.5 
24.
9 ± 
0.3 
26.
8 ± 
0.8 
23.
3 ± 
0.5 
25.
1 ± 
0.5 
27.
5 ± 
0.9 
19.
5 ± 
0.5 
22.
4 ± 
0.6 
24.
9 ± 
0.5 
24.
6 ± 
0.8 
25.
7 ± 
0.8 
27.
2 ± 
1.1 
Dispersibility 37.
8 ± 
0.2 
33.
7 ± 
0.2 
24.
6 ± 
0.8 
45.
8 ± 
1.1 
37.
4 ± 
0.6 
28.
5 ± 
0.9 
48.
1 ± 
1.2 
39.
2 ± 
0.8 
26.
5 ± 
0.5 
58.
8 ± 
0.9 
50.
1 ± 
0.5 
47.
1 ± 
0.2 
55.
3 ± 
1.2 
44.
7 ± 
0.8 
43.
4 ± 
1.2 
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Table V: Recovery (%) of BDP from each stage of the FSI and DPI (capsule, DPI, throat, 
pre-separator) as a percentage to recovered dose from batch 6-9, at 10 mg to 30 mg capsule 
fill mass using the RSO1 (n=3,  StDev). 
 
 
 
 
 
 
 
 10% BDP 
(Batch 6) 
20%BDP 
(Batch 7) 
30%BDP 
(Batch 8) 
40%BDP 
(Batch 9) 
Fill mass (mg) 10 20 30 10 20 30 10 20 30 10 20 30 
Capsule 3.3
± 
0.1 
2.8
± 
0.2 
2.3
± 
0.4 
3.7
± 
0.2 
2.8
± 
0.3 
2.3
± 
0.2 
3.7
± 
0.2 
2.8
± 
0.1 
2.4
± 
0.3 
3.8
± 
0.4 
2.9
± 
0.1 
2.3
± 
0.2 
Device 11.
9 ± 
0.1 
12.
8 ± 
0.2 
14.
1 ± 
0.5 
11.
7 ± 
0.5 
13.
8 ± 
0.2 
15.
1 ± 
0.2 
11. 
6 ± 
0.4 
13.
8 ± 
0.8 
15.
1 ± 
0.3 
11.
7 ± 
0.6 
13.
9 ± 
0.3 
15.
2 ± 
0.2 
Emitted dose 84.
7 ± 
0.3 
84.
4 ± 
0.9 
83.
2 ± 
0.2 
84.
1 ± 
1.2 
83.
5 ± 
0.5 
82.
9 ± 
0.4 
84.
7 ± 
0.7 
83.
3 ± 
0.6 
82.
8 ± 
0.9 
84.
5 ± 
0.7 
83.
2 ± 
0.3 
83.
1 ± 
0.3 
Throat 12.
4 ±  
0.1 
15.
7 ±  
0.8 
17.
7 ±  
0.6 
13.
6 ±  
1.1 
17.
5 ±  
1.1 
19.
6 ±  
0.1 
15.
8 ±  
0.4 
19.
8 ±  
1.5 
21.
5 ±  
0.8 
26.
1 ±  
0.8 
26.
7 ±  
0.2 
27.
6 ±  
0.8 
Pre-separator 20.
5 ± 
0.2 
23.
9 ± 
1.1 
26.
3 ± 
0.6 
20.
9 ± 
1.1 
26.
4 ± 
0.8 
27.
6 ± 
0.4 
24.
5 ±  
1.1 
27.
8 ±  
0.8 
29.
9 ±  
0.8 
27.
1 ±  
0.9 
29.
4 ±  
0.2 
32.
1 ± 
0.8 
Dispersibility 58.
5 ± 
0.9 
49.
8 ± 
0.5 
46.
8 ± 
0.6 
56.
7 ± 
1.1 
45.
9 ± 
1.2 
41.
6 ± 
1.3 
50.
7 ± 
1.1 
40.
7 ± 
0.9 
35.
7 ± 
0.6 
36.
6 ± 
0.5 
31.
2 ± 
0.2 
26.
5 ± 
1.1 
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3.2.8   FINE PARTICLE DOSE OF CO-MILLED FORMULATION – THE 
EFFECT OF MGST AND BDP 
 
To determine whether high dose delivery was achieved, The FPD of each formulation was 
evaluated. A general increase in FPD was associated with the increase in MGST% (w/w), the 
highest significant difference was observed between 0 and 5% MGST (w/w) co-milled 
formulations respectively (p <0.05, Figure 5A). A significant (p <0.05) reduction in FPD was 
observed between 5 and 7.5% MGST (w/w), at 20 and 30mg fill mass (Figure 5A).  
Interestingly, at low fill mass (10mg) a general increase in FPD was observed with the 
increase of MGST% (w/w), which suggest further improvements in aerosol performance 
could be achieved at higher concentrations of MGST.  
Furthermore, to increase the amount of API delivered to the lung, the capsule fill mass of the 
DPI was increased by 10 mg increments from 10 to 30 mg. The highest FPD was achieved 
from the 5% MGST (w/w) co-milled formulation at each fill mass (Figure 5A). This indicate 
further improvement in aerosol performance could be achieved at higher fill mass with 5% 
MGST (w/w). Although interesting, the investigation of higher fill mass (>30 mg) would 
likely be associated with dose loading issues and reduction of capsule rotation efficiency 
during inhalation, which could lead to the reduction in powder de-agglomeration of the 
formulation and subsequently affect the aerosol performance.  
As 5% MGST was identified as the optimal concentration in terms aerosol performance and 
FPD of BDP, co-milled formulations with increased concentration of BDP (from 1 to 40% 
w/w) was formulated in an attempt to achieve high dose delivery (in mg).  
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Generally, high dose delivery was achieved in formulations with BDP concentration greater 
than 20% (w/w) at each fill mass, with no significant increase in FPD between 30% and 40% 
(w/w) respectively (p >0.05). The highest FPD was achieved from 30% BDP (2.58mg) at 30 
mg fill mass (Figure 5B).  
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Figure 5: A) Effect of MGST% (w/w) - Fine particle dose vs fill mass, B) Effect of BDP% 
(w/w)- Fine particle dose vs fill mass. 
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3.3 CONCLUSIONS  
 
Significant (p <0.05) improvement in dispersibility and emitted dose was achieved by co-
milling 1% BDP (w/w) with concentrations of MGST from 1 to 7. 5% (w/w), with the 
optimal concentration in terms of aerosol performance and physico-chemical properties 
achieved at 5% MGST (w/w). Higher concentrations of MGST (>5% w/w) led to variability 
in the uniformity of content of the API, associated with fine particle segregation and the 
increase in agglomerate strength of the formulation, as observed from SEMs and from 
particle size shear pressure analysis, respectively. This resulted in a statistical significant 
reduction (p <0.05) in aerosol performance for the co-milled 7.5% MGST compared to 5% 
MGST (w/w) formulations, respectively. 
The increase in BDP% (w/w) concentration in the co-milled formulations at the set MGST 
concentration of 5% (w/w) generally resulted in a significant reduction in dispersibility. This 
was associated with the increase in agglomeration strength and size as observed by SEMs, 
and particle size shear pressure analysis. Furthermore, an increase in capsule fill mass of the 
RSO1 generally led to the reduction in aerosol performance of the formulations, likely due to 
a higher energy requirement for effective dispersion of the formulation at higher fill mass. 
The delivery of high dose (in mg) was generally achieved at BDP% (w/w) concentration 
greater than 20% (w/w) in the co-milled formulations. Therefore, changes associated with the 
formulation such as the concentration of the API or the additive material in addition to 
changes associated with the DPI (capsule fill mass) can lead to significant changes in the 
aerosol performance of the formulation and the energy requirements (inspiratory flow rate) to 
achieve adequate aerosol performance. This manuscript sought to understand the mechanisms 
associated with such changes and provide a guide in the design and development of future 
high dose dry powder formulations from co-milling API with additive material.  
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CHAPTER 4: EFFECT OF MGST ON STABILITY 
OF CO-MILLED FORMULATION 
 
CO-MILLED API-LACTOSE SYSTEMS FOR INHALATION THERAPY: IMPACT OF 
MAGNESIUM STEARATE ON PHYSICO-CHEMICAL STABILITY AND 
AEROSOLISATION PERFORMANCE 
 
4. INTRODUCTION 
 
The successful delivery of an active pharmaceutical ingredient (API) to the lung is primarily 
dependent upon the aerodynamic size of the particles being inhaled. In general, particles 
between 1-5 µm are considered optimal for treatment of the majority of respiratory diseases, 
while larger particles (>5 µm) are mainly deposited in the oropharynx region and are 
swallowed [1]. When delivering the API as a dry powder, high-energy comminution 
processes (most commonly air-jet micronisation) are often a necessary step to produce a 
suitable particle size distribution.  
Micronised particles are highly cohesive materials that exhibit poor flowability, de-
agglomeration and dispersibility properties [1,2]. Subsequently, the API has to be either 
blended with large inert carrier material (i.e. of a size approximately one order of magnitude 
greater than the API) [2] or agglomerated with a carrier material of similar size to form a 
sphenoid blend [3]. Both approaches improve powder handling and aerosolisation properties 
and, in general, the inert carrier material used is lactose [4]. An alternative approach to multi-
step micronisation and blending is to directly co-mill the API and carrier to achieve a 
homogeneous formulation that can be delivered as an inhaled powder [5-7]. 
  
113 
 
The process of API or carrier micronisation/milling is known to induce surface disorder in the 
crystalline structure of common small-molecule APIs and carriers [8-11]. The crystalline 
structure is typically characterised by three-dimensional long range molecular arrangements 
within the crystal lattice [12]. During the process of micronisation, the original crystalline 
material may be converted fully or partially into the amorphous state (characterised by the 
absence of long range order) and subsequently cause changes to the physical, chemical and 
biological properties of the crystalline material [12]. Furthermore, the amorphous regions are 
metastable and undergo a process of re-crystallisation during processing or storage back to 
thermodynamic equilibrium (crystalline form) which will ultimately affect various powder 
properties including particle size, dissolution, and aerosol performance [12-15]. This 
metastable transformation is generally enhanced at increased relative humidity (RH), since 
absorbed liquid vapour can act as a plasticizer [14, 16]. 
Irrespective of the degree of amorphous content in a micronised API or carrier, storage 
conditions and inter-particle forces play a critical role with respect to aerosol performance. In 
general, low humidity (<30% RH) is associated with electrostatic attraction/repulsion, 
‘normal humidity’ (50% RH) with Van der Waals forces, while at higher humidity levels 
(>75% RH), capillary forces and liquid bridges pre-dominate [17-19].  
Reduction in aerosol performance due to varied storage conditions has been shown to be 
clinically relevant. For example, an approximate 50% reduction in measured plasma 
concentrations of fluticasone in healthy subjects treated with Seretide Diskus dry powder 
inhaler (DPI) was observed after devices were stored at 75% RH at 40 ºC for 3 months, 
compared to subjects treated with a DPI stored at normal conditions (25 ºC/30% RH) [20]. 
This correlated well with in vitro data from the same study where the fine particle dose (FPD, 
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mass of particles with aerodynamic diameter ≤5 µm) decreased by >50% after storage at the 
higher humidity.  
Magnesium stearate (MGST) has traditionally been used as a lubricant in the manufacture of 
tablets as it reduces the friction between granules and the walls of compressors used during 
the manufacturing process [21]. In DPI formulations, the addition of MGST as an additive 
has been found to improve the dispersibility and flowability of conventional API/Carrier 
powder blends [22-24], and in carrier free mixtures [25]. Mechanisms hypothesised for the 
improvement in the aerosol performance of API/carrier system include the high affinity of 
MGST to the high energy active sites on carrier particles, therefore facilitating the liberation 
of API attached onto lower energy sites on the carrier [26, 27], and in the reduction of inter-
particle forces of adhesion, therefore improving the aerosolisation of agglomerated particles 
[25].  
While there has been a significant body of work focused on MGST and its role on the aerosol 
performance in dry powder formulations, its effect on the stability of formulation is less clear. 
Previous researchers have sought to demonstrate the effect of MGST in a formulation which 
consisted of lactose carriers (mean particle diameter 70.9 µm) mixed with 10% w/w MGST 
(mean particle diameter 3.3 µm) on the aerosol performance of salbutamol (2.5% w/w) before 
and after 7 days’ storage at RH of 33, 53, 75, and 84%, respectively [28]. In formulations 
without MGST, an increase in the formation of liquid bridges from moisture condensation 
between particles caused an increased in the force of adhesion between API and the lactose 
particle, which prevented the liberation of API upon inhalation. A significant reduction in 
aerosol performance was observed in the samples stored at 75 and 84% RH compared to 33% 
RH. No significant reduction in aerosol performance was found in lactose mixed with 10% 
w/w MGST. While studies in the past have focused primarily on the interactive forces 
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between coarse carrier particles and micronised particles, to the author’s knowledge an 
investigation into a particulate system consisting of micronised particles with similar sizes 
after co-milling has not been conducted. Therefore, the aim of this manuscript was to 
investigate the impact of MGST on the physico-chemical properties and aerosol performance 
of co-milled formulations which contain particles of similar size distribution.   
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4.1 MATERIALS AND METHODS 
 
4.1.1 MATERIALS 
 
Lactose (InhaLac®, Meggle group, Germany), API (Beclomethasone Dipropionate–BDP, 
Farmabios S.R.L., Italy) and magnesium stearate (MGST, Peter Greven Group, Germany) 
were used as received. Reagents used for the chemical analysis were of chromatography 
quality and supplied by Sigma (Sydney, NSW, Australia). Water used throughout the 
experiment was purified by reverse osmosis (Milli-Q, Sydney, Australia). 
4.1.2 CO-MILLED MICRO PARTICULATE SYSTEM PREPARATION 
 
An initial blend of materials (BDP, Lactose, MGST) were mixed in a steel container (radius 
1.2 cm, height 4 cm, volume 18.1 cm3) using a shaker-mixer (Hexagon Ltd, Model Alphie-
03) for 60 minutes at 32 rpm. Two 10 g formulations were prepared in the following ratio: 1-
99% w/w BDP-Lactose; 1-5-94% w/w BDP-MGST-Lactose; respectively. Each blend was 
co-milled using a jet-mill (Labo Mill Micronisation Equipment FPS 0447, Italy), at 1 g/min 
feed rate, 7 bar injection pressure, and 7 bar grinding pressure. The co-milled samples were 
stored in glass containers at controlled temperature and humidity (50% RH, 25 °C) for a 
minimum of 24 hours prior to analysis. In addition, each of the raw materials were processed 
in a similar manner to allow the study of the physico-chemical properties of the individual 
components after micronisation in comparison to the co-milled blends. Unless otherwise 
stated the two formulations are referred to as 1% BDP/99% Lactose and 1% BDP/5% MGST/ 
94% Lactose hereafter. 
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4.1.3 SCANNING ELECTRON MICROSCOPY 
 
Powder samples were placed on adhesive black carbon tabs and mounted onto aluminium 
stubs. The samples were gold coated with a sputter coater (BAL-TEC SCD 005, Tokyo, 
Japan) and particles examined under a scanning electron microscope (JEOL-JCM 6000 
NeoScope Benchtop SEM, Tokyo, Japan) at a number of magnifications using 15 keV 
accelerating voltage. 
4.1.4 PARTICLE SIZE ANALYSIS 
 
Particle size of the materials before and after milling/co-milling were determined by laser 
diffraction using a Mastersizer 3000 (Malvern, UK) equipped with Aero S dry powder 
dispersion unit.  Approximately 50 mg samples were fed through the hopper into the dry 
sample tray and 3 bar dispersion pressure was used. Measurements were taken from three 
replicates of each sample at a default refractive index (RI: 1.52) [25].  
For the analysis of co-milled samples, the default value of the RI=1.52 was used, as it would 
be difficult to determine the true value of the mixture [25]. Measurements were performed at 
3 bar dispersion pressure from three replicates of each sample and analysed using the 
Malvern Mastersizer software (Version 3.30). In addition, the co-milled samples were studied 
in terms of their response to varied shear pressure, since this is a surrogate measure of 
agglomerate strength [25]. Increasing dry powder dispersion unit shear pressures of 0.5, 1, 2, 
3 and 4 bar were used to assess the strengths of agglomerates using 50 mg powder samples. 
All sizing measurements conducted in triplicate. 
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4.1.5 DYNAMIC VAPOUR SORPTION 
 
Moisture sorption studies were undertaken using the Dynamic Vapour Sorption apparatus 
(DVS-1 surface measurement systems, London, UK). Two studies were conducted (1) 
humidity cycling from 0-90% RH and (2) one step 0-75% RH, 2 cycle, stability studies. For 
the cycling studies, approximately 100 mg of the powder sample was weighed into the DVS 
sample pan and exposed to the following experimental conditions in the DVS apparatus: a 
sorption-desorption cycle between 0 to 90% RH at 10% RH increments. A dm/dt of 0.0005% 
per minute was set as the mass equilibrium at each RH. All experiments were performed at 
25 °C. For the stability analysis, 100 mg samples were subjected to two cycles which 
consisted of a 12 h sorption phase of 75% RH and 12 h desorption phase of 0% RH. All 
experiments were performed at 25 °C. 
4.1.6 STABILITY STORAGE OF SAMPLES 
 
Approximately 500 mg of the two co-milled powder samples were placed in separate Petri 
dishes and stored in a closed container system together with a saturated solution of sodium 
chloride in a separate petri dish to achieve the storage condition of 75% RH at 25 °C. 
Humidity and temperature were monitored using a humidity and temperature probe (OEM, 
HTC-1 H596, Digital Thermometer-Humidity Hygrometer meter, Hong Kong) and samples 
were investigated after one, five and fifteen days’ storage. 
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4.1.7 AEROSOL PERFORMANCE 
The in vitro aerosol performance of the two co-milled blends before and after storage at 
different controlled environment conditions (50% RH or 75% RH for 1, 5, 15 days, 
respectively) was determined using an abbreviated impactor apparatus (FSI, Fast Screen 
Impactor, Copley, UK) consisting of a two separation stages with an aerodynamic cut-off 
diameter of ≤5 µm at 60 L/min. This means particles less than 5 μm will pass from the upper 
stages of the FSI and collected in the fine particle collection chamber.  The upper stage 
contained 15 mL of solvent (80-20% v/v methanol-water) and the lower stage contained a 
glass fibre filter (Sartorius Stedim Biotech, Glass Microfibre Discs, Diameter 80mm, 
Goettingen, Germany) secured in a filter holder. A rotary vein pump (Westech Scientific 
instruments, Bedfordshire, UK) was used to draw air through the FSI and the air-flow rate 
was adjusted to 60 L/min for 4 seconds, using a calibrated flowmeter (Model 4040, TSI 
Model Instruments, Germany). A photo of the Fast screen impactor is presented below. 
                                                         
Figure 1: Photo of the Fast screen impactor. 
10 mg co-milled powder was loaded into size 3 hydroxypropyl methylcellulose (HPMC) 
capsules (Capsugel, Peapack, New Jersey, USA) which were then inserted into high 
resistance RSO1 DPI (PlastiApe, SPA, Italy). The capsule was pierced and the DPI was 
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inserted into a mouthpiece attached to the FSI. Air was drawn through the FSI for 4 seconds 
at 60 L/min using a solenoid timer (Westech Scientific instruments, Bedfordshire, UK). All 
studies were conducted at 20 °C and 50% RH in triplicate. After actuation, the DPI, capsule, 
mouthpiece, throat, pre-separator and filter was washed with high performance liquid 
chromatography (HPLC) mobile phase and collected in volumetric flasks. HPLC results were 
processed to produce the following statistics: recovered dose RD - the total amount of BDP 
collected from the DPI and all FSI stages (effectively equivalent to the loaded or nominal 
dose) and the fine particle dose FPD -  the mass of drug deposited in the fine particle stage. 
4.1.8 HPLC ANALYSIS 
 
Quantification of assayed samples containing BDP was performed using High performance 
liquid chromatography (HPLC). A Shimadzu Prominence UFLC system was utilised for all 
chemical quantification and consisted of LC-20AT solvent delivery unit, SPD-20A UV-Vis 
detector, SIL-20A HT Autosampler (Shimadzu Corporation, Japan). The following setting 
was used for the experiment: pump flow rate 1.0 mL/min, 100 µl injection volume, 243 nm 
wavelength was used for the detection of BDP, and a NovaPak C18 column (5 µm, 150 mm x 
3.9 mm) (Waters Corporation, Milford Massachusetts, USA) used for separation. The mobile 
phase was prepared by mixing methanol (80% v/v) and water (20% v/v) which was degassed 
and filtered using 0.45 µm membrane filter (Millipore, Country Cork, Ireland) prior to the 
experiment. Linearity was obtained between 0.05-100-y µg/mL (R2 = 0.999) with a retention 
time of ~ 7.5 mins. 
4.1.9 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using Tukey One-Way Analysis of Variance (ANOVA) 
(SPSS, USA), with probability values (p) < 0.05 considered as statistically significant. 
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4.2 RESULTS AND DISCUSSION 
 
4.2.1 SCANNING ELECTRON MICROSCOPY (SEM) 
 
High resolution SEM images of the co-milled formulations after micronisation are shown in 
(Figure 2). In general, both the 1% BDP/99% Lactose and 1% BDP/5% MGST/94% Lactose 
formulations had a crystalline appearance with the majority of particles having a diameter < 
10 µm. Interestingly, the powder appeared to have two size distributions, larger particles with 
a diameter ~ 5 µm and a smaller size at ~ 1 µm. This is most likely attributed to the lactose 
and BDP components, respectively since micronisation of the components alone resulted in 
the lactose always having a larger median diameter than the BDP for any given mill setting. 
There was no clear visual difference between the 1% BDP/99% Lactose and 1% BDP/5% 
MGST/94% Lactose formulations, suggesting that the magnesium stearate component was 
milled to a similar size as the lactose or BDP and/or delaminated to form a film on the harder 
lactose and BDP surfaces during the high energy milling process. 
Figure 2: Scanning electron microscopy image of co-milled formulations containing (A) 1% 
BDP/99% Lactose and (B) 1% BDP/5% MGST/94% Lactose 
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To examine the influence of elevated storage conditions on the formulations, samples stored 
for 1, 5 and 15 days at 75% RH were taken and studied by SEM (Figure 3). For the 1% 
BDP/5% MGST/94% Lactose (Figure 3A-D) formulation, discrete fine particles of 
BDP/Lactose and MGST were observed under SEM. An increase in particle agglomeration 
after 15 days’ storage at 75% RH was observed, with an approximate average size between 
20-40 µm. The agglomerate size was not as large as that observed in the co-milled 1% 
BDP/99% Lactose formulation, with an average agglomerate size of approximately 50-100 
µm (Figure 3 E-H).    
For the co-milled 1% BDP/99% Lactose formulation, an increase in the number of large 
particle agglomerates was observed after storage at 75% RH compared to time zero (Figure 
3E –H). It is suggested that the agglomerates were formed either due to capillary forces 
between the contiguous particles and/or fusion of micronised particles resulting from 
potential surface re-crystallisation of amorphous domains that the high-energy milling 
process induces [14, 29, 30]. 
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Figure 3: SEM of co-milled formulations after storage at 50% RH (time 0) and 75% RH for 
1 to 15 days respectively. A-D: 1% BDP/5% MGST/94% Lactose at time 0, 1, 5 and 15 days, 
respectively. E-H: 1% BDP/99% Lactose at time 0, 1, 5 and 15 days, respectively 
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4.2.2 PARTICLE SIZE ANALYSIS 
 
The median (D50) particle size of the materials before and after micronisation is given in 
Figure 4. The reduction in particle size of Lactose before and after micronisation (D50 ~ 179.7 
to 5.3 µm, respectively) indicate a mixture of different particle sizes were produced. This 
result is consistent with SEM images (Figure 2) and particle size analysis (Figure 4) of co-
milled samples with the observation of large particles (>5 µm) most likely of jet milled 
lactose. In contrast to lactose, the median particle size for jet milled BDP and MGST were 
less than 5 µm (1.64 and 2.55 µm respectively) which indicate a higher fraction of the 
particles were within the size suitable for inhalation as compared to jet milled lactose. 
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Figure 4: Particle size of material before and after milling, and co-milled formulations (n=3, 
mean ± StDev). 
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In addition to standard sizing, particle size-shear analysis was performed to determine the 
agglomerate strength and thus the dispersion efficiency of the co-milled formulations after 
manufacture and storage under different conditions: 50% RH (time 0), and 75% RH for 1, 5, 
and 15 days, respectively. Particle size-shear profiles for the 1% BDP/99% Lactose and 1% 
BDP/5% MGST/94% Lactose formulations are shown in Figure 5A and B, respectively.  
In general, a higher shear pressure (ca. 2 bar) was required to produce a consistent median 
diameter for the 1% BDP/99% Lactose samples than the 1% BDP/5% MGST/94% Lactose 
(0.5 bar), at time 0 suggesting that the later formulation, containing magnesium stearate, had 
better dispersion before storage conditioning. Such observations are expected since 
magnesium stearate has previously been used as a force control agent in DPI formulations 
[23, 25].  
Upon storage, the particle size-shear pressure result of the co-milled 1% BDP/99% lactose 
formulations showed a marked increase in the recorded particle size at all tested shear 
pressures (from 0.5-4 bar) with the greatest increase observed between control and after 15 
days’ storage at 75% RH. This increase in particle size and agglomerate strength after storage 
at 75% RH from 1 to 15 days compared to control was likely due to an increase in inter-
particulate interactions between micronised lactose particles due to capillary forces and 
liquid/solid bridge formation followed by re-crystallisation as supported by findings from 
previous researchers [29-32]. In comparison, the median diameter of the 1% BDP/5% 
MGST/94% Lactose samples only increased moderately (<10 µm) and re-dispersion was 
achieved at lower shear pressures, indicating the magnesium stearate samples were less 
affected by high storage humidity, and less solid bridging was likely to have occurred.  
  
126 
 
Furthermore, in the co-milled 1% BDP/5% MGST/94% Lactose formulation, significant 
increase (p<0.05) in particle size at the various shear pressures was observed for samples 
stored at 75% RH, compared to control. However, no significant difference (p>0.05) in 
particle size was observed between the samples stored for 1, 5, or 15 days at 75% RH.  
The consistency in the particle size result after storage at different durations suggest that: 
(1) The increase in particle size between the formulation stored at 50% RH and 75% RH 
was likely due to the presence of a limited number of agglomerates in the formulation; 
these agglomerates resulted from the formation of solid bridges between exposed 
amorphous lactose surfaces during the crystallisation process after storage at high 
humidity levels. This indicates co-milling with 5% w/w MGST did not result in the 
complete surface coverage of lactose particles; 
(2) The consistency in the particle size result after storage at 75% RH for 1, 5, and 15 
days was likely due to the distribution of MGST particles on the surface of lactose 
which limited the extent of water molecule adsorption from the surrounding 
environment compared to co-milled formulation without MGST.  
Ultimately, the addition of MGST improved the stability of the co-milled 
BDP/MGST/Lactose formulation, as observed under SEM (Figure 3) as discrete fine particles 
with minimal presence of agglomeration compared to co-milled without MGST, which was 
further supported by the particle size shear results (Figure 5). Furthermore, the MGST 
containing formulation maintained a higher de-agglomeration efficiency at ~ 1-2 bar shear 
pressure, compared to the co-milled 1% BDP/99% Lactose formulation which required ~ 3-4 
bar shear pressure for de-agglomeration, after storage at 75% RH for 15 days (Figure 5). This 
indicated the co-milled 1% BDP/5% MGST/94% Lactose formulation was likely to be more 
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readily de-agglomerated into dispersive fine particles upon inhalation, and this hypothesis 
was tested in the next section by in vitro impaction analysis.  
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Figure 5: Particle size-shear profile of agglomerate strength for both co-milled formulations, 
without (A) and with (B) MGST: A) 1% BDP/99% Lactose, B) 1% BDP/5% MGST/94% 
Lactose 
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4.2.3 DYNAMIC VAPOUR SORPTION 
 
Dynamic vapour sorption (DVS) is a technique utilised to investigate the effect of humidity 
and temperature on the stability of pharmaceutical products. Specifically, it is highly sensitive 
in the detection of process such as glass-transition, hydrate formation, surface ab/adsorption 
phenomena as well as the detection of low to very low levels of amorphous content in 
predominately crystalline structures (it has been reported to have a limit of detection of ca. 
0.05%) [33]. DVS was utilised to identify the sorption/desorption profiles of the materials 
used in the production of the co-milled formulations (i.e. raw and milled materials alone) as 
well as 1% BDP/99% Lactose and 1% BDP/5% MGST/94% Lactose samples. 
Magnesium stearate is an additive with hydrophobic (class I, non hygroscopic [34]) 
properties approved by the regulatory bodies in the production of oral and inhaled 
pharmaceutical formulations [35]. The shape of its sorption/desorption isotherm is 
characteristic of a type I isotherm, a second order sorption process that approaches saturation 
with increasing RH% (Figure 6A). Materials which exhibit Type I isotherms are microporous 
solids (defined as pores with widths that do not exceed ~ 2 nm), with the uptake of water 
molecules being limited on the surface micropores [36].  The DVS result indicated a moisture 
uptake of ~ 1% w/w over the humidity range 0-90% RH, with the micronised magnesium 
stearate producing a slightly higher sorption over the raw starting material. The increase in 
moisture sorption in the jet milled magnesium stearate sample was likely due to an increase 
in the particle surface area after a reduction in particle size, which increased the amount of 
water molecules sorption. Hysteresis was not observed in the sorption/desorption isotherms 
and the isotherms were reversible.  
 
Lactose showed a minimal moisture sorption, with no hysteresis over the humidity range (0-
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90% RH) and a maximum absorption of ~ 0.05% w/w at 90% RH. In comparison, the Jet-
milled lactose produced a very different profile with approximately 0.5% moisture being 
absorbed in the first 0-90% RH cycle and hysteresis being observed during the desorption 
cycle (Figure 6A). Furthermore, the milled lactose mass change did not return to 0% upon 
drying indicating that water (ca. 0.2% w/w) was incorporated into the lactose structure. This 
was likely due to a re-crystallisation process in the mill induced amorphous domains of the 
material and is likely to promote irreversible agglomeration of the material. Such 
observations are consistent with previous reports [37, 38].  
No difference in the sorption and desorption profile of BDP was observed before or after 
milling with approximately 0.5% w/w being absorbed over the range 0-90% RH (Figure 6A). 
Differences in the sorption/desorption isotherms were observed for the co-milled 
formulations (Figure 6B). In general, the 1% BDP/99% Lactose formulation showed a similar 
profile to that of the jet-milled lactose alone (Figure 6A) where approximately 0.5% w/w 
moisture was absorbed in the first sorption cycle with the mass not returning to zero upon 
drying. Such observations suggest a significant amount of crystallisation had occurred in the 
formulation that was most likely attributed to the lactose component. In comparison, the 1% 
BDP/5% MGST/94% Lactose sample showed a reversible sorption profile, with the sample 
absorbing ~ 0.4% w/w at 90% RH. This mass sorption was likely to be attributed to the BDP 
and MGST components in the formulation since MGST absorbs ~ 1% w/w at 90% RH and 
BDP ~ 0.5% w/w. To further investigate this, the sorption of co-milled sample containing just 
MGST and lactose was studied (5% MGST/95% Lactose). It was observed, again, that a 
reversible sorption isotherm was obtained with approximately 0.2% w/w being absorbed at 
90% RH (Figure 6B). 
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Figure 6: Sorption/desorption profile of: A) materials before and after micronisation, B) co-
milled formulations. 
To further study the impact of storage conditions on formulation stability a two-cycle (12 h), 
two-step (0-75% RH) stability study was conducted (Figure 7). For the 1% BDP/99% 
Lactose, irreversible sorption/desorption was observed in the first cycle as the sample 
absorbed ~ 0.5% w/w moisture at 75% RH which did not return to zero after the desorption 
131 
 
cycle, as ~ 0.3% w/w water was incorporated in the sample from the re-crystallisation of 
lactose (Figure 7A). Hysteresis between the sorption/desorption profile in the second cycle 
was not observed, as the sample absorbed ~ 0.2% w/w of moisture and returned to the re-
crystallised weight (~ 0.3% w/w).  
For the 1% BDP/5% MGST/94% Lactose (Figure 7B), an improvement in formulation 
stability was observed, with ~ 0.3% w/w moisture absorption in the first cycle which was 
approximately reversible with a return to ~ 0.01% w/w. This result was repeated in the 
second sorption/desorption cycle. 
From the DVS results, the primarily difference between the two co-milled formulations was 
the presence of hysteresis in the sorption/desorption cycle for the 1% BDP/99% Lactose 
formulation, which was not observed in the co-milled with MGST formulation (Figure 6B 
and Figure 7). This suggests the addition of MGST into the milling process resulted in a more 
stable formulation with limited or no crystallisation. This may be due to (1) the MGST 
forming a protective coating on the amorphous region of the lactose, preventing moisture 
ingression and crystallisation and/or, (2) the prevention of amorphous domain formation on 
the lactose by MGST during the milling process.  
The DVS results were consistent with results from SEM and particle size-shear analysis, as 
the re-crystallisation of the amorphous domains of micronised lactose led to an increase in 
fine particle agglomeration and agglomerate strength respectively for the co-milled 1% 
BDP/99% Lactose formulation compared to co-milled with MGST (Figure 3 and 5). In-vitro 
impaction study was conducted in the next section to determine the effect of physico-
chemical changes in the formulation on the aerosol performance of the two co-milled 
formulations.  
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Figure 7: DVS of co-milled formulations after storage at 0% RH and 75% RH over a 48-hour 
period. (A) 1% BDP/99% Lactose and (B) 1% BDP/5% MGST/94% Lactose. 
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4.2.4 AEROSOL PERFORMANCE 
 
The aerosol performance of the co-milled formulations was compared after storage at the 
different conditions (Time 0 (50% RH) and 75% RH for 1, 5, 15 days, respectively). From a 
formulation perspective, the dispersibility of the API is largely dependent on the strength of 
the inter-particulate forces between particles. Under SEM, co-milled formulations were 
observed as agglomerates of fine particles, and the aerosol performance is largely dependent 
on the strength of cohesion and adhesion between BDP-BDP and between BDP-Lactose 
particles, respectively. In the case of the co-milled formulation containing magnesium 
stearate, the lubricating nature of the additive is likely to reduce the interaction between BDP 
and lactose resulting in significantly higher de-agglomeration efficiency. This was observed 
in the particle sizing studies as well as in the aerosol performance presented here. In general, 
for a 100 µg nominal dose, the FPD of BDP was 29.9 µg ± 0.7 µg for 1% BDP/99% Lactose 
compared to 41.8 µg ± 2.5 µg for 1% BDP/5% MGST/94% Lactose, indicating the co-milled 
with MGST formulation had a higher de-agglomeration efficiency and improved aerosol 
performance (Figure 8A) 
Upon storage at 75% RH, the performance (FPD) of the 1% BDP/99% Lactose formulation 
decreased significantly (p<0.05) from 29.9 µg ± 0.7 µg to 10.0 µg ± 1.1 µg after 15 days’ 
storage. In comparison, the FPD of the 1% BDP/5% MGST/94% Lactose only decreased to 
36.3 µg ± 2.9 µg after storage at 75% RH for 15 days, indicating better formulation stability 
at elevated humidity. 
It is important to note that since the initial FPD of the two formulations are different, it is 
difficult to evaluate the relative change in performance. In order to do this, the FPD was 
normalised at time 0 measurement and plotted (Figure 8B). Comparison of the normalised 
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FPD data for the 1% BDP/99% Lactose compared to the 1% BDP/5% MGST/94% Lactose 
formulations suggested that the performance deteriorated at a much greater rate for the 
formulation that did not contain co-milled MGST. After 15 days’ storage, the FPD of 1% 
BDP/99% Lactose was less than 40% of its initial value, while the 1% BDP/5% MGST/94% 
Lactose being still within 80% of the starting value.  
Such observations are likely to be due to a combination of reasons. Firstly, the adhesion and 
cohesion between the contiguous particles is less for the magnesium stearate containing 
formulation, making de-agglomeration easier in general, irrespective of storage humidity. 
Such observations could be correlated with particle sizing studies reported here (Figure 5). 
Secondly, a greater amount of agglomeration was observed under SEM for the 1% BDP/99% 
Lactose samples after storage (Figure 3), suggesting increased cohesion and adhesion within 
this sample.  
Lastly, a physico-chemical transformation was observed with respect to moisture sorption 
(Figure 6B), suggesting re-crystallisation of amorphous domains in the co-milled 1% 
BDP/99% Lactose sample, which would result in irreversible solid bridging between 
contacting particles and an overall increase in particle size. This effect would significantly 
reduce the aerosolisation efficiency as seen in the 1% BDP/99% Lactose formulation (Figure 
8). In comparison, the 1% BDP/5% MGST/94% Lactose formulation did not present an 
irreversible moisture sorption profile (Figure 6B), indicating magnesium stearate presented a 
protecting effect that was reflected in the reduced impact of humidity on aerosolisation 
performance as a function of storage. 
 
135 
 
                 
Figure 8: (A) Fine particle dose (FPD)and (B) normalized FPD co-milled formulations as a 
function of storage time at 75% RH. Time 0 is storage at 50% RH. (n=3, mean ± StDev)  
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4.3 CONCLUSIONS 
 
The effect of MGST on the physico-chemical properties and aerosol performance of co- 
milled formulations were investigated. As observed under high resolution SEM, storage of 
the co-milled formulations at elevated humidity (75% RH) for 15 days caused an increase in 
the number of larger agglomerates (~ 50-100 µm) for 1% BDP/99% Lactose compared to an 
approximate agglomerate size of 20-40 µm for 1% BDP/5% MGST/94% Lactose 
formulation, respectively. Furthermore, particle size-shear analysis indicated a difference in 
the agglomerate strength between the co-milled formulations after storage at 75% RH for 15 
days, with a higher shear pressure required for powder de-agglomeration (~ 3-4 bar) in the 
1% BDP/99% Lactose sample, compared to a lower shear pressure of ~ 1-2 bar for the 1% 
BDP/5% MGST/94% Lactose sample, respectively. This was likely due to differences in the 
physico-chemical properties of the particles upon exposure to elevated humidity: for 1% 
BDP/99% Lactose, the re-crystallisation of amorphous regions on micronised lactose 
particles was observed from hysteresis in the sorption/de-sorption profile from DVS, which 
likely caused significant capillary interactions and solid bridge formation between particles. 
In contrast, no hysteresis was observed in the corresponding sorption/de-sorption profile for 
1% BDP/5% MGST/94% Lactose, as the presence of MGST likely minimised the re-
crystallisation of amorphous regions on micronised lactose particles by either the formation 
of a surface coat on micronized particles by MGST or limiting amorphous domains formation 
during the co-milling process with MGST.  
The differences in the physico-chemical properties ultimately led to differences in the aerosol 
performance of the formulations, as a greater reduction in the fine particle dose was observed 
for the 1% BDP/99% Lactose compared to 1% BDP/5% MGST/94% Lactose after storage at 
elevated humidity level (reduction in normalised FPD to less than 40% of its initial value 
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after storage at 15 days compared to FPD within 80% of its initial value, respectively). This 
indicated co-milling with MGST is a viable option in the improvement of the physico-
chemical properties and aerosol performance of co-milled dry powder formulations upon 
storage at elevated humidity, likely due to a combination of the following factors such as 1) 
surface coverage by MGST that reduced the extent of cohesive/adhesive interactions between 
micronized particles 2) coating of the amorphous regions on lactose particles by MGST 
which prevented recrystallization after storage at high humidity  3) limiting amorphous 
region domain formation during the co-milling process. 
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CHAPTER 5: GENERAL CONCLUSIONS AND 
FUTURE WORK 
 
5.1 GENERAL CONCLUSIONS 
 
In this thesis it has been demonstrated that high dose delivery (in mg) can be achieved by co-
milling the API with an additive, BDP and MGST, respectively, using the jet mill apparatus 
for the production of dry powder formulation with improved physico-chemical properties and 
aerosol performance as reported in chapter 3 and 4 respectively.  
The investigation into the effect of MGST% w/w concentration in co-milled (by jet mill) 
formulations indicated 5% w/w MGST was the optimal concentration in terms of reduction in 
agglomerate strength, and improved aerosol performance compared to co-milled without 
MGST. Further increase in MGST% w/w concentration to 7.5% w/w led to failure in 
uniformity of content, increased agglomerate strength, and reduction in aerosol performance 
compared to co-milled formulation with 5% w/w MGST, likely due to fine particle 
segregation which increased the number of inter/intra particulate interactions and 
subsequently led to an overall increase in agglomerate strength and size. 
The investigation into the effect of variable BDP% w/w concentrations in the co-milled 
formulations at the set concentration of MGST (5% w/w) indicated that in general, a decrease 
in aerosol performance was observed as the concentration of BDP in the formulation 
increased. Physico-chemical analysis indicated that an increase in BDP% w/w augmented the 
extent of cohesive interactions between micronised BDP particles, observed as dense, 
cohesive agglomerates under SEM, with reduced dispersibility properties as measured from 
particle size-shear pressure and in-vitro aerosol performance analysis.  
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Furthermore, while high dose delivery was achieved at BDP% w/w concentration greater 
than 20% w/w at the tested capsule fill mass; a general reduction in aerosol performance was 
observed with the increase in capsule fill mass, likely due to higher energy requirement to 
achieve higher powder dispersion. 
The effect of humidity on aerosol performance and physico-chemical properties was also 
investigated between two co-milled formulations 1% BDP/5% MGST/94% Lactose and 1% 
BDP/99% Lactose, before and after storage at elevated relative humidity (75% RH) for 1, 5, 
15 days respectively. In general, prolonged storage at 75% RH led to the reduction in aerosol 
performance, with significantly higher aerosol performance for the co-milled 5% w/w MGST 
formulation. This was likely due to the hydrophobic property of the MGST which reduced 
the extent of moisture adsorption and subsequently the re-crystallisation of amorphous 
regions on the surface of micronised lactose particles. Therefore, co-milling with MGST was 
shown to improve the stability of the formulation after storage at elevated humidity levels 
compared to the co-milled formulation without MGST.  
This study demonstrated the significant impact of MGST and API concentration on the 
aerosol performance and physico-chemical properties of co-milled dry powder formulations 
for high dose pulmonary delivery 
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5.2 FUTURE WORK 
 
The aerosol performance of micronised particles is primarily dependent on the extent of 
inter/intra particulate interactions. This study demonstrated that by co-milling (by the jet mill 
apparatus) the API with MGST, the interactions between particles are reduced and an 
improvement in the dispersibility of the formulation is observed compared to co-milling 
without MGST.  
Further studies should investigate:  
1) The effect of MGST concentration on the in vitro dissolution of BDP in simulated lung 
fluids; and 
2) Compare the aerosol performance of co-milled formulations produced from other milling 
apparatus, such as the ball mill. 
Such studies will further strengthen the case for the application of co-milled formulations as a 
viable option in the expanding field of high dose delivery. 
 
 
 
 
 
